US20160256511A1 - Compositions and methods for the treatment or prophylaxis of circadian protein related conditions - Google Patents
Compositions and methods for the treatment or prophylaxis of circadian protein related conditions Download PDFInfo
- Publication number
- US20160256511A1 US20160256511A1 US14/431,097 US201414431097A US2016256511A1 US 20160256511 A1 US20160256511 A1 US 20160256511A1 US 201414431097 A US201414431097 A US 201414431097A US 2016256511 A1 US2016256511 A1 US 2016256511A1
- Authority
- US
- United States
- Prior art keywords
- composition
- extract
- disease
- sirt1
- clock
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 76
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 37
- 238000011282 treatment Methods 0.000 title claims description 24
- 230000002060 circadian Effects 0.000 title description 17
- 238000011321 prophylaxis Methods 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 150
- 230000014509 gene expression Effects 0.000 claims abstract description 113
- 102000000344 Sirtuin 1 Human genes 0.000 claims abstract description 70
- 108010041191 Sirtuin 1 Proteins 0.000 claims abstract description 70
- 108010088547 ARNTL Transcription Factors Proteins 0.000 claims abstract description 65
- 102000008867 ARNTL Transcription Factors Human genes 0.000 claims abstract description 64
- 102100037315 F-box/LRR-repeat protein 3 Human genes 0.000 claims abstract description 57
- 102100027753 Putative F-box/LRR-repeat protein 21 Human genes 0.000 claims abstract description 52
- 240000009206 Hemerocallis fulva Species 0.000 claims abstract description 39
- 235000002941 Hemerocallis fulva Nutrition 0.000 claims abstract description 39
- 230000027288 circadian rhythm Effects 0.000 claims abstract description 38
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 21
- 230000008569 process Effects 0.000 claims abstract description 20
- 244000178231 Rosmarinus officinalis Species 0.000 claims abstract description 9
- 101001026868 Homo sapiens F-box/LRR-repeat protein 3 Proteins 0.000 claims abstract 17
- 101000862167 Homo sapiens Putative F-box/LRR-repeat protein 21 Proteins 0.000 claims abstract 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 111
- 201000010099 disease Diseases 0.000 claims description 91
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 33
- 229940096998 ursolic acid Drugs 0.000 claims description 28
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 28
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 20
- 230000002159 abnormal effect Effects 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 12
- 208000021642 Muscular disease Diseases 0.000 claims description 12
- 208000008589 Obesity Diseases 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 208000012902 Nervous system disease Diseases 0.000 claims description 9
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 208000019116 sleep disease Diseases 0.000 claims description 9
- 208000020685 sleep-wake disease Diseases 0.000 claims description 9
- 201000007034 advanced sleep phase syndrome Diseases 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 201000001098 delayed sleep phase syndrome Diseases 0.000 claims description 8
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 7
- 230000036772 blood pressure Effects 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 230000002503 metabolic effect Effects 0.000 claims description 7
- 208000020016 psychiatric disease Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 201000001421 hyperglycemia Diseases 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 206010019133 Hangover Diseases 0.000 claims description 4
- 208000013016 Hypoglycemia Diseases 0.000 claims description 4
- 201000009623 Myopathy Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 208000033923 irregular sleep wake type circadian rhythm sleep disease Diseases 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 201000004559 cerebral degeneration Diseases 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000007056 liver toxicity Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000012672 seasonal affective disease Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 75
- 235000020748 rosemary extract Nutrition 0.000 description 54
- 229940092258 rosemary extract Drugs 0.000 description 54
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 54
- 101710083635 F-box/LRR-repeat protein 3 Proteins 0.000 description 40
- 101710126388 F-box/LRR-repeat protein 21 Proteins 0.000 description 35
- 241001529742 Rosmarinus Species 0.000 description 30
- 230000001965 increasing effect Effects 0.000 description 28
- 238000000605 extraction Methods 0.000 description 23
- 239000000306 component Substances 0.000 description 15
- 108010075228 CLOCK Proteins Proteins 0.000 description 14
- 102000008025 CLOCK Proteins Human genes 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 230000010410 reperfusion Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 238000010166 immunofluorescence Methods 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- XLIJUKVKOIMPKW-BTVCFUMJSA-N [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XLIJUKVKOIMPKW-BTVCFUMJSA-N 0.000 description 9
- -1 FBX121 Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101150032765 ARNTL gene Proteins 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000011990 Sirtuin Human genes 0.000 description 4
- 108050002485 Sirtuin Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 239000003855 balanced salt solution Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000027747 Kennedy disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000002730 additional effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000002565 arteriole Anatomy 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008632 circadian clock Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100038419 Circadian locomoter output cycles protein kaput Human genes 0.000 description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 102000018700 F-Box Proteins Human genes 0.000 description 2
- 108091072033 F-box protein family Proteins 0.000 description 2
- 208000001730 Familial dysautonomia Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 208000035172 MERRF Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010036049 Polycystic ovaries Diseases 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 2
- 201000001638 Riley-Day syndrome Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 244000307585 akino wasuregusa Species 0.000 description 2
- 235000006822 akino wasuregusa Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000012268 mitochondrial disease Diseases 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 201000005936 periventricular leukomalacia Diseases 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102100037211 Aryl hydrocarbon receptor nuclear translocator-like protein 1 Human genes 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010006542 Bulbar palsy Diseases 0.000 description 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000033895 Choreoacanthocytosis Diseases 0.000 description 1
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 description 1
- 208000017164 Chronobiology disease Diseases 0.000 description 1
- 101710197111 Circadian locomoter output cycles protein kaput Proteins 0.000 description 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 101000831686 Drosophila melanogaster Protein cycle Proteins 0.000 description 1
- 108700011215 E-Box Elements Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 244000207620 Euterpe oleracea Species 0.000 description 1
- 235000012601 Euterpe oleracea Nutrition 0.000 description 1
- 239000002714 Extracts of rosemary Substances 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000756137 Hemerocallis Species 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 101000740484 Homo sapiens Aryl hydrocarbon receptor nuclear translocator-like protein 1 Proteins 0.000 description 1
- 101000882921 Homo sapiens Circadian locomoter output cycles protein kaput Proteins 0.000 description 1
- 101000640050 Homo sapiens Protein strawberry notch homolog 1 Proteins 0.000 description 1
- 101000667092 Homo sapiens Vacuolar protein sorting-associated protein 13A Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000021272 Laurelia serrata Species 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000234269 Liliales Species 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 208000035177 MELAS Diseases 0.000 description 1
- 201000009035 MERRF syndrome Diseases 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 208000019090 Machado-Joseph disease type 3 Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010070909 Metabolic cardiomyopathy Diseases 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000896229 Mus musculus Aryl hydrocarbon receptor nuclear translocator-like protein 1 Proteins 0.000 description 1
- 101001073214 Mus musculus Period circadian protein homolog 2 Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000002131 PAS domains Human genes 0.000 description 1
- 108050009469 PAS domains Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010047728 Period Circadian Proteins Proteins 0.000 description 1
- 102000007001 Period Circadian Proteins Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
- 101100496572 Rattus norvegicus C6 gene Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010041216 Sirtuin 2 Proteins 0.000 description 1
- 102000000477 Sirtuin 2 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000002548 Spastic Paraparesis Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000032859 Synucleinopathies Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100039114 Vacuolar protein sorting-associated protein 13A Human genes 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 235000003650 acai Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 244000288972 chang guan xuan cao Species 0.000 description 1
- 235000006147 chang guan xuan cao Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000008675 chorea-acanthocytosis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 235000019306 extracts of rosemary Nutrition 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 1
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000010522 hyperproinsulinemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 208000007431 neuroacanthocytosis Diseases 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 210000003137 popliteal artery Anatomy 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000001282 primary progressive aphasia Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 201000000196 pseudobulbar palsy Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 125000002220 ursolic acid group Chemical group 0.000 description 1
- 210000001125 vasa nervorum Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A23L1/3002—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Definitions
- the present invention relates to dietary supplement compositions containing rosemary or Hemerocallis fulva extracts and methods for treatment of prophylaxis of conditions related to a circadian rhythm.
- Circadian rhythms control a variety of biological processes, including sleep/wake cycles, body temperature, hormone secretion, gastrointestinal function, metabolic glucose homeostasis, and immunological functions.
- Biological clocks exhibiting circadian rhythms exist in virtually all tissues, with a series of clock genes generating the rhythm through protein feedback effects on their own synthesis.
- CLOCK-BMAL1 is a core component of the molecular clock machinery that drives circadian gene expression and physiology in mammals.
- CLOCK and BMAL1 are each basic helix-loop-helix (bHLH) PAS-domain transcription factors that together form the positive elements of the central oscillatory loop.
- CLOCK and BMAL1 form a heterodimer that binds to E-box elements in the promoters of target genes.
- CLOCK:BMAL1 Some of the primary genes under transcriptional control by CLOCK:BMAL1 encode the three Period (mPer1, mPer2, and mPer3) proteins and two Cryptochromegenes (mCry1 and mCry2) proteins. Following translation of the Per and Cry proteins, they translocate to the nucleus where they act as potent inhibitors of CLOCK:BMAL1-induced gene transcription forming a negative feedback loop and regulating the rhythmic expression of many genes.
- the PERIOD protein mPER2 the gene of which is also under CLOCK:BMAL1 transcriptional control, functions as a stimulator of Bmal1 transcription, forming the positive feedback loop and enhancing CLOCK:BMAL1 activity. The regulation of these positive and negative feedback loops regulates the circadian rhythm within the cell.
- SIRT1 a nicotinamide adenine dinucleotide-dependent sirtuin
- BMAL1 circadian rhythm
- SIRT1 controls circadian clock circuitry and promotes cell survival providing a connection with age-related neoplasms.
- circadian function decays with aging in normal mice, and boosting their SIRT1 levels in the brain could prevent this decay.
- loss of SIRT1 function impairs circadian control in young mice, mimicking what happens in normal aging.
- SIRT1 has been shown to exert this control by regulating the genes BMAL1 and CLOCK, the two major keepers of the central circadian clock.
- Oxygen and circadian rhythmicity are essential in a myriad of physiological processes to maintain homeostasis, from blood pressure and sleep/wake cycles, as well as in cellular signaling pathways that play critical roles in health and disease. Oxidative stress can induce the dysregulated circadian rhythms. Thus, there is a need for new compositions and methods for regulating proper protein expression and circadian rhythm.
- the present inventions provide methods of ameliorating or preventing the effects of stress in a subject by the administration of particular compositions that reverse physiological responses to stress.
- compositions for the treatment or prevention of a disease or condition related to the expression of a circadian rhythm related protein including: an effective amount of an extract of rosemary, an extract of hemerocallis fulva , active portion or component thereof, or combinations thereof, said extract formulated for administering to a subject in need of treatment of a disease or condition related to a circadian rhythm; and ameliorating, preventing, or modulating a symptom of said disease or condition in said subject whereby said effective amount is sufficient to alter one or more expression characteristics of a protein selected from the group consisting of CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof, in said subject.
- an extract is optionally water extract.
- an extract or active portion or component thereof is optionally a portion of or used solely as a dietary supplement.
- an extract includes ursolic acid at 10% by weight or greater, optionally 25% by weight or greater.
- An extract is optionally solely ursolic acid.
- ursolic acid is an active component or portion of an extract.
- a composition includes or consists of ursolic acid.
- a composition is optionally administered at or between ⁇ 4 hours to 12 hours after light exposure.
- the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between ⁇ 4 hours to 0 hours prior to light exposure.
- Administration is optionally once daily, twice daily, more frequently, or on an as needed basis.
- Administration is optionally for a period of 2 weeks or more, optionally 4 weeks or more, optionally three months or more.
- a disease or condition that is treated or prevented is optionally jet lag. Treating or ameliorating jet lag is optionally achieved by administration prior to or following travel involving a change in time zone.
- a disease or condition is a hangover.
- An extract, active portion or component thereof, is optionally administered prior to, during, or following the consumption of alcohol, or combinations thereof.
- a disease or condition is metabolic condition related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.
- a metabolic condition is optionally abnormal cholesterol level, obesity, metabolic syndrome or element thereof, hyperglycemia, hypoglycemia, abnormal insulin production, or diabetes.
- a disease or condition is an inflammatory disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a disease or condition is a neurological disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a neurological disorder is optionally Alzheimer's disease.
- a disease or condition is a muscular disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a muscular disorder is optionally muscular dystrophy or myopathy.
- a disease or condition is a sleep disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a sleep disorder is optionally insomnia, jet lag, shift work sleep disorder, delayed sleep phase syndrome (DSPS), advanced sleep phase syndrome (ASPS), non 24-hour sleep wake disorder or irregular sleep-wake pattern.
- administration is optionally at or between ⁇ 4 hours to 12 hours after light exposure.
- the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between ⁇ 4 hours to 0 hours prior to light exposure.
- Administration is optionally once daily, twice daily, more frequently, or on an as needed basis.
- a disease or condition is a psychiatric disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a psychiatric disorder is optionally depression, seasonal affective disorder, dementia, or rapid-cycling bipolar disorder.
- a disease or condition is a cardiovascular disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a cardiovascular disorder is abnormal blood pressure or abnormal heart rate.
- a cardiovascular disorder is atherosclerosis or cardiomyopathy.
- a disease or condition is a liver toxicity related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a disease or condition is a disorder of the brain related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a disorder of the brain is stroke or brain degeneration due to free radicals.
- a disease or condition is obesity.
- a disease or condition is a cellular proliferative disorder, optionally cancer.
- a composition optionally includes 10% or greater ursolic acid, optionally 25% or greater ursolic acid.
- a composition optionally consists of ursolic acid.
- a composition optionally consists essentially of ursolic acid and excludes other compositions that are useful for the treatment or prevention of a disease.
- a composition is optionally provided as a dietary supplement or component thereof.
- a dietary supplement is optionally in the form of a powder, gel, liquid, food, solid, or other form.
- compositions are similarly suitable for use in processes essentially as described for the prevention or treatment of a disease or condition related to the expression of a circadian rhythm related protein.
- a process includes administering to a subject in need of treatment or amelioration of a disease or condition related to expression of a protein selected from the group consisting of CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof, composition including an effective amount of an extract of rosemary, an extract of hemerocallis fulva , active portion or component thereof, or combinations thereof.
- An composition optionally includes ursolic acid at 10% by weight or greater, optionally 25% or greater, optionally solely including ursolic acid, or ursolic acid as the sole active directed to treatment or prevention of the disease or condition.
- a composition is optionally provided as a dietary supplement or component thereof.
- a dietary supplement is optionally in the form of a powder, gel, liquid, food, solid, or other form.
- a disease or condition that is treated or prevented is optionally jet lag. Treating or ameliorating jet lag is optionally achieved by administration prior to or following travel involving a change in time zone.
- a disease or condition is a hangover.
- An extract, active portion or component thereof, is optionally administered prior to, during, or following the consumption of alcohol, or combinations thereof.
- a disease or condition is metabolic condition related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1.
- a metabolic condition is optionally abnormal cholesterol level, obesity, metabolic syndrome or element thereof, hyperglycemia, hypoglycemia, abnormal insulin production, or diabetes.
- a disease or condition is an inflammatory disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a disease or condition is a neurological disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a neurological disorder is optionally Alzheimer's disease.
- a disease or condition is a muscular disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a muscular disorder is optionally muscular dystrophy or myopathy.
- a disease or condition is a sleep disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a sleep disorder is optionally insomnia, jet lag, shift work sleep disorder, delayed sleep phase syndrome (DSPS), advanced sleep phase syndrome (ASPS), non 24-hour sleep wake disorder or irregular sleep-wake pattern.
- administration is optionally at or between ⁇ 4 hours to 12 hours after light exposure.
- the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between ⁇ 4 hours to 0 hours prior to light exposure.
- Administration is optionally once daily, twice daily, more frequently, or on an as needed basis.
- a disease or condition is a psychiatric disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a psychiatric disorder is optionally depression, seasonal affective disorder, dementia, or rapid-cycling bipolar disorder.
- a disease or condition is a cardiovascular disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a cardiovascular disorder is abnormal blood pressure or abnormal heart rate.
- a cardiovascular disorder is atherosclerosis or cardiomyopathy.
- a disease or condition is a liver toxicity related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a disease or condition is a disorder of the brain related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- a disorder of the brain is stroke or brain degeneration due to free radicals.
- a disease or condition is obesity.
- a disease or condition is a cellular proliferative disorder, optionally cancer.
- a composition is optionally administered at or between ⁇ 4 hours to 12 hours after light exposure.
- the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between ⁇ 4 hours to 0 hours prior to light exposure.
- Administration is optionally once daily, twice daily, more frequently, or on an as needed basis.
- Administration is optionally for a period of 2 weeks or more, optionally 4 weeks or more, optionally three months or more.
- FIG. 1A illustrates the effects of RME and HFE on CLOCK protein expression in C6 cells
- FIG. 1B illustrates the effects of RME and HFE on CLOCK protein expression in C6 cells
- FIG. 2A illustrates RME increased BMAL1 protein levels in 4 hr oxygen-glucose deprivation (OGD) and 2 hr reperfusion treated C6 cells;
- FIG. 2B illustrates RME increased FBXL21 protein levels in 4 hr oxygen-glucose deprivation (OGD) and 2 hr reperfusion treated C6 cells;
- FIG. 3A illustrates SIRT1 levels increased in OGD Rat L-6 cells treated with RME, HFE, or both;
- FIG. 3B illustrates quantifiable increases in SIRT1 levels in OGD treated Rat L-6 cells
- FIG. 4A illustrates CLOCK protein levels increased in OGD Rat L-6 cells treated with RME, HFE, or both;
- FIG. 4B illustrates quantifiable increases in CLOCK levels in OGD treated Rat L-6 cells by RME, HFE, or both;
- FIG. 5A illustrates Bmal1 protein levels increased in OGD Rat L-6 cells treated with RME, HFE, or both;
- FIG. 5B illustrates quantifiable increases in Bmal1 levels in OGD treated Rat L-6 cells by RME, HFE, or both;
- a circadian rhythm machinery component is understood as altering, optionally increasing, the expression level, post-translational modification state, nuclear or cytoplasmic location or translocation, or RNA expression rate of a protein normally involved in a 24-hour or other regular cycle in one or more cell types in a subject.
- a circadian machinery component is optionally RNA or protein, or modifications thereof that are or encode CLOCK, BMAL1, SIRT1, FBXL3, FBXL21, or combinations thereof.
- a disease or condition is one that is due to an irregularity, undesirable expression characteristic, or other element that is caused directly or indirectly by one or more of CLOCK, BMAL1, SIRT1, FBXL3, or FBXL21, or RNA encoding one or more of such proteins.
- a process includes administering to a subject having a disease or condition associated with an undesirable circadian rhythm function and in need of such treatment an effective amount of an extract of rosemary, an extract of hemerocallis fulva , active portion thereof, or combinations thereof or a dietary supplement containing in whole or in part of an extract of rosemary, an extract of hemerocallis fulva , active portion thereof, or combinations thereof.
- Such an administration is at an administration time.
- the administration of the extract of rosemary, an extract of hemerocallis fulva , active portion thereof, or combinations thereof or a dietary supplement containing such will alter an expression characteristic of a protein of CLOCK, BMAL1, FBXL3, FBX121, SIRT1, or combinations thereof in the subject.
- the invention has utility for treating, preventing, or otherwise modulating a condition caused directly or indirectly by altering or adjusting one or more expression characteristics of a protein involved in a circadian rhythm in a cell.
- An “expression characteristic” is the transcription of a gene encoding a circadian rhythm protein, translation of RNA encoding a circadian rhythm protein, localization of RNA encoding a circadian rhythm protein, protein function, protein localization, protein post-translational modification, or other parameter recognized in the art related to protein expression and function.
- the disease or condition is a sleep disorder, optionally insomnia, jet lag, shift work sleep disorder, delayed sleep phase syndrome (DSPS), advanced sleep phase syndrome (ASPS), a non-24-hour sleep wake disorder or irregular sleep-wake pattern.
- disease or condition is a psychiatric disorder associated with circadian rhythm, optionally depression.
- the disease or disorder is a neurological disease with a circadian rhythm component, optionally Alzheimer's disease or anorexia nervosa.
- the disease or disorder is abnormal blood pressure.
- the disease or disorder is abnormal heart rate.
- the disease or disorder is asthma.
- a disease or condition is excess fat tissue, elevated body mass index, or other weight disorder.
- a disease or condition is or is an increased risk of a brain injury such as by ischemic stroke.
- a disease or condition is related to free radical induced degeneration of brain tissue.
- a disease or condition is less than desirable muscle mass.
- a disease or condition is the need for muscle recovery following exercise.
- a disease or condition is cortisol suppression.
- a disease or condition is undesirable testosterone levels.
- a disease or condition is a hangover or other condition related to abnormal hydration or salt levels.
- a disease or condition is excess inflammation at one or more sites or systemic inflammation.
- a disease or condition is atherosclerosis.
- a disease or condition is hyperglycemia or hypoglycemia.
- a disease or condition is the presence of a toxin in a subject or liver disorder resulting or related to the presence of a toxin.
- the disease or disorder is anorexia nervosa.
- the disease or condition is abnormal blood pressure.
- the disease or condition is abnormal heart rate.
- the disease or condition is asthma.
- the disease or condition is a metabolic disorder.
- the metabolic disorder is diabetes, abnormal insulin secretion, abnormal plasma glucose levels, obesity, or metabolic syndrome (or element thereof).
- the disease or condition is cancer.
- treating comprises ameliorating symptoms of the disease or condition.
- a disease or condition is a metabolic disorder.
- Specific metabolic disorders, diseases or conditions optionally include insulin resistance, diabetes, diabetes related conditions or disorders, or metabolic syndrome.
- a disease or condition is a cardiovascular disease.
- Cardiovascular diseases that can be treated or prevented include cardiomyopathy or myocarditis, illustratively idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy.
- a cardiovascular disease is atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta or other coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, or the popliteal arteries.
- vascular diseases that can be treated or prevented include those related to the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems.
- a disease or condition is a neurological disease.
- Neurological diseases illustratively include neurodegenerative diseases optionally including stroke, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, Multiple Sclerosis (MS), Friedreich's ataxia, Periventricular leukomalacia (PVL), ALS-Parkinson's-Dementia complex of Guam, Wilson's disease, cerebral palsy, progressive supranuclear palsy (Steel-Richardson syndrome), bulbar and pseudobulbar palsy, diabetic retinopathy, multi-infarct dementia, macular degeneration, Pick's disease, diffuse Lewy body disease, prion diseases such as Creutzfeldt-Jakob, Gerstmann-Straussler-Scheinker disease, Kuru and fatal familial insomnia
- a disease or condition is a muscular disease.
- Muscular diseases illustratively include neuromuscular diseases such as muscular dystrophy and myopathy.
- a disease or condition is a mitochondrial disease.
- Mitochondrial diseases optionally include KSS (chronic progressive external ophthalmoplegia), MERRF (myoclonus epilepsy associated with ragged-red fibers; Fukuhara syndrome), MELAS, Leber's disease, Leigh encephalopathia and Pearson's disease.
- a disease or condition is an insulin related condition.
- Insulin resistance disorders include any disease or condition that is caused by or contributed to by insulin resistance.
- Illustrative non-limiting examples include diabetes, obesity, metabolic syndrome, insulin-resistance syndromes, syndrome X, insulin resistance, high blood pressure, hypertension, high blood cholesterol, dyslipidemia, hyperlipidemia, dyslipidemia, atherosclerotic disease including stroke, coronary artery disease or myocardial infarction, hyperglycemia, hyperinsulinemia and/or hyperproinsulinemia, impaired glucose tolerance, delayed insulin release, diabetic complications, including coronary heart disease, angina pectoris, congestive heart failure, stroke, cognitive functions in dementia, retinopathy, peripheral neuropathy, nephropathy, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis some types of cancer (such as endometrial, breast, prostate, and colon), complications of pregnancy, poor female reproductive health (such as menstrual irregularities,
- compositions in solid, semi-solid, or liquid dosage forms, such as, for example, tablets, chewables, suppositories, pills, capsules, powders, liquids, or suspensions, and may be provided in unit dosages suitable for a single administration.
- Time release preparations are also contemplated as effective dosage formulations.
- compositions may include an effective amount of a selected extract of rosemary, hemerocallis fulva , active portion thereof, or combinations, optionally in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents.
- the extracts are recognized to include an active ingredient as an active portion of an extract, or the sole portion of an extract.
- Active ingredient refers a component present in the extract that renders, directly or indirectly, the intended effect of the extract.
- an active ingredient is ursolic acid.
- Extraction parameters such as water quality, heating temperature, drying temperature, heating time, drying time, and filtering processes all contribute to the quality and efficiency of the process. Water quality directly affects the concentration of active ingredient(s). Poor quality water may cause active ingredient(s) to become decomposed or oxidized during or following the extraction process.
- the rosemary or hemerocallis fulva may be obtained from various resources.
- Rosemary, or Rosmarinus officinalis is a woody bush native to the Mediterranean region. Extracts of rosemary may be made from Rosmarinus spp. and preferably from the leaves and young flowering tops of fresh rosemary ( Rosmarinus officinalis L. and its cultivars). Rosemary extraction may be performed by harvesting the leaves of a rosemary plant and reducing them in size such as by chopping to improve solvent penetration. A typical particle size is optionally 0.5-5.0 mm, or any value or range therebetween. In some aspects, the leaf is chopped into a powder type substance with a particle size of less than 0.5 mm.
- the chopped plant material is combined with a suitable extraction solvent such as water and/or a low molecular weight alcohol (e.g. C4-C6 alcohol) such as ethanol.
- a suitable extraction solvent such as water and/or a low molecular weight alcohol (e.g. C4-C6 alcohol) such as ethanol.
- the plant material is combined with the solvent for an extraction time of 18 to 36 hours.
- the extraction temperature is optionally the range 10° C. to 45° C.
- the resulting extract liquid is separated from the solid material and filtered, optionally with a sterile filter.
- the resulting extract is poured onto nonstick tray and allowed to dry at 80-90° C. Vacuum-spray dry equipment is optionally used for the drying procedure.
- the resulting dry extract powder is weighed. An extraction ratio is calculated as w/20 ⁇ 100% with w as the weight (g) of the dry extract powder.
- the sample and water ratio, heat time, volume of water in the second extraction may vary depending on the amount of the
- Extracts of Hemerocallis fulva are optionally obtained from extraction in an extraction solvent such as water and/or low molecular weight alcohol such as ethanol. Extracts are prepared from plants belonging to the genus Hemerocallis of the family Liliaceae of the order Liliales are used. Examples of such plants include Akinowasuregusa ( Hemerocallis fulva L. sempervirens M. Hotta or Hemerocallis sempervirens Araki), Honkanzo ( Hemerocallis fulva L. var. fulva ), Nokanzo ( Hemerocallis fulva L. var.
- An extract is optionally prepared from whole plants or plant parts, such as leaves, stems, and roots.
- an extract is prepared by drying the plant material and optionally cutting the material into a suitable size for extraction, such as the sizes described for rosemary.
- the plant material is combined with an extraction solvent (e.g. water, aqueous buffer, low molecular weight alcohol, or combinations thereof) that is preheated to a temperature of 60° C. to 100° C. for an extraction time, typically of 20 to 90 minutes.
- the particulate material is then removed by gravity separation, centrifugation, or filtering, optionally with a filter size suitable for aseptic filtration.
- the resulting extract is optionally poured onto nonstick tray and allowed to dry at 80-90° C. Vacuum-spray dry equipment is optionally used for the drying procedure.
- the resulting dry extract powder is weighed. An extraction ratio is calculated as w/20 ⁇ 100% with w as the weight (g) of the dry extract powder.
- the sample and water ratio, heat time, volume of water in the extraction may vary depending on the amount of the raw material used for extraction.
- a second extraction of either plant material is performed optionally using the same extraction parameters or differing extraction parameters.
- a second extraction is performed in a low molecular weight alcohol optionally of C 2 -C 4 .
- the first and second extraction solutions are optionally combined together and dried.
- an extract includes or consists of ursolic acid as an active ingredient.
- Ursolic acid is optionally present in an extract at a concentration of 10 weight percent or greater.
- ursolic acid is present in an extract at a concentration of 25 weight percent or greater.
- ursolic acid is present at a weight percent at or in excess of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, or 99.9.
- ursolic acid is descried as a component of or the product representing an extract
- extract may in some aspects include otherwise isolated, purified, or chemically synthesized ursolic acid.
- an “extract” is in some aspects ursolic acid obtained either by extraction from a natural or non-natural source, or used as a chemically synthesized ursolic acid.
- the extract can be in pharmaceutical compositions in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, or suspensions, and may be provided in unit dosages suitable for a single administration. Time release preparations are specifically contemplated as effective dosage formulations.
- the compositions will include an effective amount of the selected extract in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents.
- conventional nontoxic solid carriers may include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talc, cellulose, glucose, sucrose and magnesium carbonate.
- Liquid pharmaceutically administrable compositions may, for example, be prepared by dissolving or dispersing an active compound with optimal pharmaceutical adjuvants in an excipient, such as water, saline, aqueous dextrose, glycerol, or ethanol, to form a solution or suspension.
- the pharmaceutical composition may contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, for example, sodium acetate or triethanolamine oleate.
- wetting or emulsifying agents such as wetting or emulsifying agents, pH buffering agents, for example, sodium acetate or triethanolamine oleate.
- pH buffering agents for example, sodium acetate or triethanolamine oleate.
- fine powders or granules of extract, or a liquid extract may contain diluting, dispersing, or surface active agents.
- the extract may be presented in water or in syrup, in capsules or sachets in the dry state, or in a non-aqueous solution or suspension.
- Suspending agents may also be included in tablets, which may include binders and lubricants in a suspension. Flavoring, preserving, suspending, thickening, or emulsifying agents may be also included to modify the taste and texture of the composition.
- the tablets and granules provided for oral administration may further be coated for ease of digestion.
- the extract containing dietary supplement composition may be combined with one or more other active agents.
- An active agent optionally functions synergistically with an extract material.
- Active agents illustratively include vitamins (such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E or vitamin K), antioxidants (such as acai, wolfberry, alpha lipoic acid, astazanthin, or fucoxanthin), or other regulators of one or more circadian rhythm protein (illustratively resveratrol or polygonum), or any combination of the above.
- the extract according to the present invention is available as a food additive thereto. Examples include foods in a liquid, semi-liquid, solid, paste, or jelly form.
- a subject is defined as an organism (such as a human, non-human primate, equine, bovine, murine, or other mammal), or a cell.
- a cell include neuronal cells, muscle cells, or any other cell that endogenously or exogenously expresses a circadian machinery component protein.
- Circadian rhythm protein expression is altered when a cell, optionally a cell in an organism, is contacted by an extract of rosemary, an extract of hemerocallis fulva , or combinations thereof.
- Illustrative examples of proteins include the proteins CLOCK, BMAL1, FBXL3, FBX121, SIRT1. In some aspects, a protein is not a sirtuin protein.
- the Circadian Locomotor Output Cycles Kaput (CLOCK) protein is optionally altered in one or more expression characteristics in aspects of the invention.
- CLOCK protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes.
- an extract is an extract of rosemary that increases expression of a CLOCK protein.
- an extract is an extract of hemerocallis fulva that increases expression of a CLOCK protein.
- Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva , or combinations thereof is shown to increase the expression of CLOCK protein within 2 hours of administration.
- CLOCK protein expression is enhanced (e.g.
- CLOCK protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- BMAL1 Brain and muscle Arnt-like protein-1
- MOP3 a transcription factor known to regulate circadian rhythm.
- BMAL1 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes.
- an extract is an extract of rosemary that increases expression of a BMAL1 protein.
- an extract is an extract of hemerocallis fulva that increases expression of a BMAL1 protein.
- Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva , or combinations thereof is shown to increase the expression of BMAL1 protein within 2 hours of administration.
- BMAL1 protein expression is enhanced (e.g.
- BMAL1 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- F-box/LRR-repeat protein 3 is a member of the F-box protein family that functions in phosphorylation-dependent ubiquitination.
- FBXL3 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes.
- an extract is an extract of rosemary that increases expression of a FBXL3 protein.
- an extract is an extract of hemerocallis fulva that increases expression of a FBXL3 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva , or combinations thereof is shown to increase the expression of FBXL3 protein within 2 hours of administration.
- FBXL3 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween.
- FBXL3 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- F-box/LRR-repeat protein 21 is a member of the F-box protein family that functions in phosphorylation-dependent ubiquitination.
- FBXL21 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes.
- an extract is an extract of rosemary that increases expression of a FBXL21 protein.
- an extract is an extract of hemerocallis fulva that increases expression of a FBXL21 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva , or combinations thereof is shown to increase the expression of FBXL21 protein within 2 hours of administration.
- FBXL21 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween.
- FBXL21 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- Sirtuin 1 is a protein involved in deacetylation of proteins that contribute to cellular regulation.
- SIRT1 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes.
- an extract is an extract of rosemary that increases expression of a SIRT1 protein.
- an extract is an extract of hemerocallis fulva that increases expression of a SIRT1 protein.
- Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva , or combinations thereof is shown to increase the expression of SIRT1 protein within 2 hours of administration.
- SIRT1 protein expression is enhanced (e.g.
- SIRT1 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- circadian protein expression is detected and optionally quantified by enzyme linked immunosorbent assay (ELISA), mass spectrometry, western blot, gel electrophoresis optionally coupled with staining such as by Coomassie brilliant blue or silver stain, or by target specific stains, flow cytometry, immunoprecipitation, or by other method known in the art.
- ELISA enzyme linked immunosorbent assay
- mass spectrometry mass spectrometry
- western blot gel electrophoresis optionally coupled with staining such as by Coomassie brilliant blue or silver stain, or by target specific stains, flow cytometry, immunoprecipitation, or by other method known in the art.
- an ELISA is used to detect and optionally quantify circadian protein expression.
- ELISA kits for SIRT1 and SIRT2 are available from Enzo Lifesciences, Plymouth Meeting, Pa. Kits for other sirtuins are similarly available from commercial sources.
- Antibodies directed to CLOCK, BMAL1, and SIRT proteins suitable for use in ELISA, western blot, immunofluorescence or other applications are available from Santa Cruz Biotechnology, Santa Cruz, Calif.
- Anti-FBXL21 and anti-FBXL3 antibodies are available from abcam, Cambridge, Mass.
- a process optionally includes administration of an extract or dietary supplement containing extract at an administration time in an amount effective to treat the disease or condition or otherwise modulate or ameliorate a symptom of such a disease of condition.
- Administration is optionally once daily, twice daily or more.
- Administration optionally is done 1, 2, 3, 4 or more times each day.
- administration is done on an as needed basis.
- administration is done once or twice weekly such as when a subject is transitioning from one schedule to another such as due to travel, shift work, weekend to work schedule or work to weekend schedule, or other necessary time.
- an administration time is following exercise.
- an administration time when one or more symptoms of a disease or condition are present, or conditions exist that such a symptom is expected or may occur.
- administration is prior to, following, during, or in lieu of a meal, snack or other consumption of food or nutritious drink.
- administration is prior to, during or following the consumption of alcohol.
- an administration time is at the initiation of a work period.
- Administration time is optionally from ⁇ 4 hours to 12 hours following light exposure.
- administration is from 0 to 12 hours after light exposure.
- an administration time is upon waking independent of the time of day or the onset of light exposure.
- an administration time is in the evening.
- An administration time may be tailored to a desired time to have expression of such a protein or collection of proteins expressed to adjust the sleep-wake cycle of a subject, or to improve wakefulness at a desired time with the improvement in wakefulness optionally, not due to improved rest.
- the extract is administered in a form that releases at certain times, optionally in an extended release form, in a periodic release form, or using a time control pump.
- the extract materials are taken orally between one and three times daily; although, other routes of administration may be utilized.
- the extracts of the present invention may be utilized in the form of derivatives.
- the extracts may be bonded, chemically or physically, to other species and moieties such as synthetic polymers, liposomes, small organic molecules, chitin, chitosan, other biopolymers and the like.
- a subject is administered a composition in a dosage so that each dose of the extract supplement selected to deliver an amount of active agent suitable to have an effect on an expression characteristic of a circadian protein.
- Variable dosing regimens are operative. While in some instances, a single dose treatment may be effective in producing therapeutic effects, in other instances a treatment period in the range of, for example, six weeks to three or six months or more may be utilized.
- the composition may be administered orally, parentally, or intravenously, intramuscularly, intraperitoneally, by transdermal injection, or by contact with a cell or tissue such as by immersion or other form of contact.
- injectables may be prepared in conventional forms, either liquid solutions or suspensions, solid forms suitable for solution or prior to injection, or as suspension in liquid prior to injection or as emulsions.
- the extracts may be provided in sterile form and contain an effective amount of one or more agents for producing the desired response in a unit of weight or volume suitable for administration to a subject.
- the doses of extracts or dietary supplements containing gone or more of the extracts are administered to a subject can be chosen in accordance with different parameters in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.
- the dosage of a pharmacological agent may be adjusted by the individual physician or veterinarian, particularly in the event of any complication.
- the dose of the composition may vary depending on the age, weight, general condition of the subject.
- dosage is in the range of 1-1,000 mg of equivalent of dry extract powder extract per day may be an effective range.
- a dosage is between 10 and 800 mg per day, optionally from 100 to 600 mg per day, optionally 200-400 mg per day, optionally 400 mg per day.
- Dosage is optionally 1, 2, 3, 4, or more times daily.
- dosage is twice daily.
- dosage is 200 mg twice daily.
- the extract may also comprise 0.01%-100% of the dry weight of the composition.
- a dietary supplement composition may comprise 20%-50% of the dry weight of the extract composition.
- An “effective amount” is defined as that capable of altering one or more expression characteristics of a circadian protein or a gene encoding a circadian protein relative to a control.
- An extract optionally is or is a part of a dietary supplement composition.
- An extract is optionally present in a dietary supplement composition at 10%-100% by weight, optionally 20%-50% by weight, optionally 30%-40% by weight, or any value or range between 10% and 100% of the dry weight of the dietary supplement composition.
- the dried rosemary extract and hemerocallis fulva extract were provided by Integrity Nutraceuticals International (Spring Hill, Tenn., USA).
- the dried powder of each extract contains 25% ursolic acid.
- the dried rosemary or Hemerocallis fulva powder (1 g) was incubated with an aqueous phosphate buffer solution 0.01 M, pH 7.4 (5 mL), at 60° C. for 4 hours, then centrifuged at 6000 rpm for 15 minutes. The supernatant was filtrated by 40 ⁇ m filter mesh and saved for the concentration evaluation. Aliquots of RME and HFE were prepared at 10 mg/mL and stored at ⁇ 20° C. for use in subsequent studies.
- C6 glioma cells (CCL-107) were purchased from American Type Culture Collection (ATCC; Manassas, Va.). Cell cultures were grown in F-12 K medium (Gibco/Invitrogen) supplemented with 10% horse serum and 2% fetal bovine serum and maintained at 37° C. with 5% CO 2 /95% air. Cultures were grown to 85% confluency in 75 mm flasks and, after trypsinization, were seeded in 35 mm culture dishes or 6 well plates; and grown to confluence during the experimental period. All cultures were used in the experiments between passages 22 and 32. Plated cells were grown for 2 days before treatment with an extract or control.
- IPEC-1 cells were carried out at 37° C. in an atmosphere containing 5% CO 2 .
- Undifferentiated IPEC-1 cells were maintained in serial passage in growth medium (GM): DMEM/F12 medium supplemented with 5% FBS, insulin, transferrin (ITS Premix), epidermal growth factor, penicillin and streptomycin. Cells were maintained in serum-containing GM for 48 h for the experiments.
- GM growth medium
- FBS fetal bovine serum
- ITS Premix transferrin
- epidermal growth factor penicillin and streptomycin
- the cells were stained with the primary antibody for the target of interest followed by incubation with AlexaFluor® 594-conjugated normal rabbit IgG (green) or AlexaFluor® 488-conjugated normal mouse IgG (red).
- C6 cells were treated with saline with or without RME (20, 50 and 100 ⁇ g/mL) or without HFE (50, 100 and 200 ⁇ g/mL) in the medium for 2 h at 37° C.
- RME rosemary extract
- HFE hemerocallis fulva extract
- CLOCK protein kaput
- IPEC-1 cells were treated with saline with or without RME (20, 50 and 100 ⁇ g/mL) or with or without HFE (50, 100 and 200 ⁇ g/mL) in the medium for 6 h at 37° C. 6 h RME and HFE treatment significantly induced the intensity of immunofluorescence of CLOCK compared with the controls.
- FIG. 1 illustrates the effects of RME and HFE on CLOCK ( FIG. 1A ) and BMAL1 ( FIG. 1B ) protein expression in C6 cells.
- C6 cells were treated with saline with or without RME (20 and 50 ⁇ g/mL) or with or without HFE (50 and 100 ⁇ g/mL) in the medium for 7 h at 37° C. Representative immunoblots show increased expression in RME and HFE treated C6 cells.
- Oxygen glucose deprivation was induced in cultures as described by Panickar et al. (Panickar et al., 2009a). Briefly, cultures were washed twice with a balanced salt solution (BSS) with the following composition (in mM): NaCl 116, KCl 5.4, CaCl 2 1.8, MgSO 4 0.8, NaH 2 PO 4 0.83, NaHCO 3 24 and phenol red 0.001 w/v; pH 7.4. Following washes, BSS was added to the cultures and placed in an airtight container (Billups chamber; Billups-Rothenberg Inc., Del Mar, Calif.) and continuously flushed with 95% N2/5% CO 2 for 5 hr. Following the OGD, BSS was removed and normal media was added immediately afterwards.
- BSS balanced salt solution
- Oxygen-glucose deprivation (OGD)-induced decreased CLOCK expression is reversed and further enhanced by RME and HFE in IPEC-1 cells.
- the RME and HFE were added to the media during 4 hr OGD and added to normal media for other 3 hr, immediately after the end of 4 hr OGD at 37° C.
- Sample photomicrographs of CLOCK fluorescence after 4 hr OGD and 3 h reperfusion in normal control (CON), OGD, and OGD+two dosages RME or HFE 100 ⁇ g/ml or 200 ⁇ g/ml illustrate increases in CLOCK expression relative to control and OGD treated cells.
- FIG. 2 illustrates RME increased BMAL1 (A) and FBXL21 (B) protein levels in 4 hr oxygen-glucose deprivation (OGD) and 2 hr reperfusion treated C6 cells.
- the RME was added to the media during 4 hr OGD and added to normal media for other 2 hr, immediately after the end of 4 hr OGD at 37° C.
- the blot bands are detected by Odyssey® Western Blotting.
- the blot was probed with rabbit anti-BMAL1 or mouse anti-FBX121 followed by detection with IRDye® 800CW Goat anti-Rabbit IgG (LI-COR P/N 926-32231) or IRDye 680RD Goat anti-Mouse IgG (LI-COR P/N 926-68070).
- IRDye® 800CW Goat anti-Rabbit IgG LI-COR P/N 926-32231
- IRDye 680RD Goat anti-Mouse IgG LI-COR P/N 926-68070.
- RME or HFE The effects of RME or HFE on SIRT1 protein expression in 4 hr oxygen-glucose deprivation (OGD) and 2 hr reperfusion treated C6 cells were examined by immunofluorescence.
- the RME or HFE were added to the media during 4 hr OGD and added to normal media for other 2 hr, immediately after the end of OGD at 37° C.
- SIRT1 fluorescence was increased in RME and HFE at either 50 ⁇ g/ml or 100 ⁇ g/ml in 4 hr OGD and 2 hr reperfusion treated C6 cells.
- Rat L-6 myogenic cell line (ATCC) were grown as a monolayer in DMEM with 10% fetal bovine serum (FBS) at 37° C. in a humidified incubator with 5% CO 2 .
- L-6 cells (0.5 ⁇ 10 6 ) were seeded on 6-well plates. Experiments were initiated 48 hr after plating.
- OGD oxygen-glucose deprivation
- the culture media was replaced with hypoglycemic media and placed in an airtight Billups chamber and flushed with 95% N 2 /5% CO 2 for 4 hr.
- hypoglycemic media was replaced with regular media and returned to the incubator, with or without RME, HFE or the mixture of RME/HFE for 20 hr.
- the cells were washed twice with cold PBS, and harvested by scraping in 200 ⁇ l of lysis buffer. Eighty micrograms of protein, which was determined by Bradford assay (Bio-Rad protein assay kit) was separated electrophoretically using a 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel and transferred to a nitrocellulose membrane.
- the membrane was incubated at room temperature in Odyssey blocking buffer including 0.05% Tween-20 containing primary antibodies as above directed to one of the following: SIRT1 (1:500), CLOCK (1:2000), Bmal1 (1:1000), or ⁇ -actin (1:1000). After washing with TBS-T three times, the membrane was incubated with anti-mouse or rabbit IRDye secondary antibodies (1:10,000) for 1 h at room temperature. Quantitative IR western blot detection was performed with Odyssey CLx Imager. Data were analyzed by one-way analysis of variance followed by post-hoc analysis of between group mean differences by Fisher's Least Significant Difference (LSD) test. Different superscripts indicate significant differences among groups (p ⁇ 0.05).
- LSD Least Significant Difference
- SIRT1 levels are increased in OGD treated L-6 cells by RME and/or HFE.
- the quantified amounts of protein are illustrated in FIG. 3B demonstrating significantly increased amounts of SIRT1 levels relative to control.
- An additional effect is observed in RME+HFE mixture treated cells on SIRT1 expression, compared with individual RME or HFE only treated cells.
- FIG. 4 illustrates CLOCK protein levels increased in OGD treated L-6 cells by RME and/or HFE.
- RME, HFE, or both significantly enhance CLOCK protein expression in OGD treated L6 skeletal muscle cells.
- An additional effect in RME+HFE mixture treated cells on CLOCK expression is also observed compared to individual RME or HFE only treated cells.
- FIG. 5 illustrates Bmal1 protein levels increased in OGD treated L-6 cells by RME and/or HFE.
- RME, HFE, or both significantly enhance Bmal1 protein expression in OGD treated L-6 skeletal muscle cells.
- An additional effect is observed in cells treated with the RME+HFE compared with individual RME or HFE only treated cells.
- Ursolic Acid Enhances the Expression of Circadian Rhythm Proteins
- iPEC-1 cells were grown as a monolayer in DMEM with 10% fetal bovine serum (FBS) and the necessary supplements at 37° C. in a humidified incubator with 5% CO 2 .
- iPEC1 cells were seeded on 35 mm dishes. Experiments were initiated 48 hr after plating. Cells were treated with saline or with ursolic acid at three separate dosages (1 ⁇ M; 5 ⁇ M; or 20 ⁇ M) in the medium for 24 hr at 37° C. The cells were then washed with ice-cold PBS and fixed with 4% paraformaldehyde for 10 min at room temperature followed by permeabilization with 0.3% Triton X-100 for 10 min.
- FBS fetal bovine serum
- Immunological methods e.g., preparation of antigen-specific antibodies, immunoprecipitation, and immunoblotting are described, e.g., in Current Protocols in Immunology, ed. Coligan et al., John Wiley & Sons, New York, 1991; and Methods of Immunological Analysis, ed. Masseyeff et al., John Wiley & Sons, New York, 1992.
- Patents, publications, and applications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents, publications, and applications are incorporated herein by reference to the same extent as if each individual patent, publication, or application was specifically and individually incorporated herein by reference.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
Abstract
Description
- This application depends from and claims priority to U.S. Provisional Application No. 61/903,434 filed Nov. 13, 2013, and U.S. Provisional Application No. 61/903,440 filed Nov. 13, 2013, the entire contents of each of which are incorporated herein by reference
- The present invention relates to dietary supplement compositions containing rosemary or Hemerocallis fulva extracts and methods for treatment of prophylaxis of conditions related to a circadian rhythm.
- Living organisms from cyanobacteria to mammals display circadian rhythms (i.e., oscillations with 24-h periodicities) in multiple physiological and behavioral processes. These rhythms are found in nearly all living organisms. Circadian rhythms are generated endogenously and function under tightly regulated genetic control.
- Circadian rhythms control a variety of biological processes, including sleep/wake cycles, body temperature, hormone secretion, gastrointestinal function, metabolic glucose homeostasis, and immunological functions. Biological clocks exhibiting circadian rhythms exist in virtually all tissues, with a series of clock genes generating the rhythm through protein feedback effects on their own synthesis.
- These multiple endogenous clocks are distributed in every cell of the organism, which may result in each organ having its own timed circadian rhythm. A complex mechanism of activation and feedback regulate the expression, post-translational modification, translocation, and degradation of circadian proteins. The transcription factor complex CLOCK-BMAL1 is a core component of the molecular clock machinery that drives circadian gene expression and physiology in mammals. CLOCK and BMAL1 are each basic helix-loop-helix (bHLH) PAS-domain transcription factors that together form the positive elements of the central oscillatory loop. CLOCK and BMAL1 form a heterodimer that binds to E-box elements in the promoters of target genes. Some of the primary genes under transcriptional control by CLOCK:BMAL1 encode the three Period (mPer1, mPer2, and mPer3) proteins and two Cryptochromegenes (mCry1 and mCry2) proteins. Following translation of the Per and Cry proteins, they translocate to the nucleus where they act as potent inhibitors of CLOCK:BMAL1-induced gene transcription forming a negative feedback loop and regulating the rhythmic expression of many genes. The PERIOD protein mPER2, the gene of which is also under CLOCK:BMAL1 transcriptional control, functions as a stimulator of Bmal1 transcription, forming the positive feedback loop and enhancing CLOCK:BMAL1 activity. The regulation of these positive and negative feedback loops regulates the circadian rhythm within the cell.
- SIRT1, a nicotinamide adenine dinucleotide-dependent sirtuin, has been shown to promote cell survival by inhibiting apoptosis or cellular senescence in mammalian cells. Recent studies have provided a link between the cellular metabolic function of SIRT1 and the circadian rhythm (controlled by the CLOCK:BMAL1 machinery) where it has been shown that SIRT1 controls circadian clock circuitry and promotes cell survival providing a connection with age-related neoplasms. Also, circadian function decays with aging in normal mice, and boosting their SIRT1 levels in the brain could prevent this decay. Conversely, loss of SIRT1 function impairs circadian control in young mice, mimicking what happens in normal aging. Moreover, SIRT1 has been shown to exert this control by regulating the genes BMAL1 and CLOCK, the two major keepers of the central circadian clock.
- Oxygen and circadian rhythmicity are essential in a myriad of physiological processes to maintain homeostasis, from blood pressure and sleep/wake cycles, as well as in cellular signaling pathways that play critical roles in health and disease. Oxidative stress can induce the dysregulated circadian rhythms. Thus, there is a need for new compositions and methods for regulating proper protein expression and circadian rhythm.
- The following summary of the invention is provided to facilitate an understanding of some of the innovative features unique to the present invention and is not intended to be a full description. A full appreciation of the various aspects of the invention can be gained by taking the entire specification, claims, drawings, and abstract as a whole.
- Maintenance of normal hemostasis is vital to a healthy physiology. Stresses in a subject can result in physiological changes that destroy this hemostasis. The present inventions provide methods of ameliorating or preventing the effects of stress in a subject by the administration of particular compositions that reverse physiological responses to stress.
- Provided are processes and compositions for the treatment or prevention of a disease or condition related to the expression of a circadian rhythm related protein including: an effective amount of an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof, said extract formulated for administering to a subject in need of treatment of a disease or condition related to a circadian rhythm; and ameliorating, preventing, or modulating a symptom of said disease or condition in said subject whereby said effective amount is sufficient to alter one or more expression characteristics of a protein selected from the group consisting of CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof, in said subject.
- In the processes or compositions, an extract is optionally water extract. Optionally an extract or active portion or component thereof is optionally a portion of or used solely as a dietary supplement. In some aspects, an extract includes ursolic acid at 10% by weight or greater, optionally 25% by weight or greater. An extract is optionally solely ursolic acid. In some aspects, ursolic acid is an active component or portion of an extract. Optionally a composition includes or consists of ursolic acid.
- A composition is optionally administered at or between −4 hours to 12 hours after light exposure. In some aspects, the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between −4 hours to 0 hours prior to light exposure. Administration is optionally once daily, twice daily, more frequently, or on an as needed basis. Administration is optionally for a period of 2 weeks or more, optionally 4 weeks or more, optionally three months or more.
- A disease or condition that is treated or prevented is optionally jet lag. Treating or ameliorating jet lag is optionally achieved by administration prior to or following travel involving a change in time zone.
- In some aspects, a disease or condition is a hangover. An extract, active portion or component thereof, is optionally administered prior to, during, or following the consumption of alcohol, or combinations thereof.
- In some aspects, a disease or condition is metabolic condition related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1. A metabolic condition is optionally abnormal cholesterol level, obesity, metabolic syndrome or element thereof, hyperglycemia, hypoglycemia, abnormal insulin production, or diabetes.
- In some aspects, a disease or condition is an inflammatory disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- In some aspects, a disease or condition is a neurological disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. A neurological disorder is optionally Alzheimer's disease.
- In some aspects, a disease or condition is a muscular disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. A muscular disorder is optionally muscular dystrophy or myopathy.
- In some aspects, a disease or condition is a sleep disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. A sleep disorder is optionally insomnia, jet lag, shift work sleep disorder, delayed sleep phase syndrome (DSPS), advanced sleep phase syndrome (ASPS), non 24-hour sleep wake disorder or irregular sleep-wake pattern. For a sleep disorder administration is optionally at or between −4 hours to 12 hours after light exposure. In some aspects, the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between −4 hours to 0 hours prior to light exposure. Administration is optionally once daily, twice daily, more frequently, or on an as needed basis.
- In some aspects, a disease or condition is a psychiatric disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. A psychiatric disorder is optionally depression, seasonal affective disorder, dementia, or rapid-cycling bipolar disorder.
- In some aspects, a disease or condition is a cardiovascular disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. Optionally, a cardiovascular disorder is abnormal blood pressure or abnormal heart rate. In some aspects, a cardiovascular disorder is atherosclerosis or cardiomyopathy.
- In some aspects, a disease or condition is a liver toxicity related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- In some aspects, a disease or condition is a disorder of the brain related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. Optionally, a disorder of the brain is stroke or brain degeneration due to free radicals.
- In some aspects, a disease or condition is obesity.
- In some aspects, a disease or condition is a cellular proliferative disorder, optionally cancer.
- A composition optionally includes 10% or greater ursolic acid, optionally 25% or greater ursolic acid. A composition optionally consists of ursolic acid. A composition optionally consists essentially of ursolic acid and excludes other compositions that are useful for the treatment or prevention of a disease. A composition is optionally provided as a dietary supplement or component thereof. A dietary supplement is optionally in the form of a powder, gel, liquid, food, solid, or other form.
- The compositions are similarly suitable for use in processes essentially as described for the prevention or treatment of a disease or condition related to the expression of a circadian rhythm related protein. A process includes administering to a subject in need of treatment or amelioration of a disease or condition related to expression of a protein selected from the group consisting of CLOCK, BMAL1, FBXL3, FBXL21, SIRT1, or combinations thereof, composition including an effective amount of an extract of rosemary, an extract of hemerocallis fulva, active portion or component thereof, or combinations thereof. An composition optionally includes ursolic acid at 10% by weight or greater, optionally 25% or greater, optionally solely including ursolic acid, or ursolic acid as the sole active directed to treatment or prevention of the disease or condition. A composition is optionally provided as a dietary supplement or component thereof. A dietary supplement is optionally in the form of a powder, gel, liquid, food, solid, or other form.
- Process are provided for treatment or prevention of one or more of a variety of conditions. A disease or condition that is treated or prevented is optionally jet lag. Treating or ameliorating jet lag is optionally achieved by administration prior to or following travel involving a change in time zone.
- In some aspects, a disease or condition is a hangover. An extract, active portion or component thereof, is optionally administered prior to, during, or following the consumption of alcohol, or combinations thereof.
- In some aspects, a disease or condition is metabolic condition related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, or SIRT1. A metabolic condition is optionally abnormal cholesterol level, obesity, metabolic syndrome or element thereof, hyperglycemia, hypoglycemia, abnormal insulin production, or diabetes.
- In some aspects, a disease or condition is an inflammatory disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- In some aspects, a disease or condition is a neurological disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. A neurological disorder is optionally Alzheimer's disease.
- In some aspects, a disease or condition is a muscular disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. A muscular disorder is optionally muscular dystrophy or myopathy.
- In some aspects, a disease or condition is a sleep disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. A sleep disorder is optionally insomnia, jet lag, shift work sleep disorder, delayed sleep phase syndrome (DSPS), advanced sleep phase syndrome (ASPS), non 24-hour sleep wake disorder or irregular sleep-wake pattern. For a sleep disorder administration is optionally at or between −4 hours to 12 hours after light exposure. In some aspects, the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between −4 hours to 0 hours prior to light exposure. Administration is optionally once daily, twice daily, more frequently, or on an as needed basis.
- In some aspects, a disease or condition is a psychiatric disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. A psychiatric disorder is optionally depression, seasonal affective disorder, dementia, or rapid-cycling bipolar disorder.
- In some aspects, a disease or condition is a cardiovascular disorder related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. Optionally, a cardiovascular disorder is abnormal blood pressure or abnormal heart rate. In some aspects, a cardiovascular disorder is atherosclerosis or cardiomyopathy.
- In some aspects, a disease or condition is a liver toxicity related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1.
- In some aspects, a disease or condition is a disorder of the brain related to an expression characteristic of one or more of CLOCK, BMAL1, FBXL3, FBXL21, of SIRT1. Optionally, a disorder of the brain is stroke or brain degeneration due to free radicals.
- In some aspects, a disease or condition is obesity.
- In some aspects, a disease or condition is a cellular proliferative disorder, optionally cancer.
- A composition is optionally administered at or between −4 hours to 12 hours after light exposure. In some aspects, the administration time occurs at or between 0 hours to 12 hours after light exposure, optionally at or between 1 hours to 3 hours after light exposure or 10-14 hours after light exposure, optionally at or between −4 hours to 0 hours prior to light exposure. Administration is optionally once daily, twice daily, more frequently, or on an as needed basis. Administration is optionally for a period of 2 weeks or more, optionally 4 weeks or more, optionally three months or more.
-
FIG. 1A illustrates the effects of RME and HFE on CLOCK protein expression in C6 cells; -
FIG. 1B illustrates the effects of RME and HFE on CLOCK protein expression in C6 cells; -
FIG. 2A illustrates RME increased BMAL1 protein levels in 4 hr oxygen-glucose deprivation (OGD) and 2 hr reperfusion treated C6 cells; -
FIG. 2B illustrates RME increased FBXL21 protein levels in 4 hr oxygen-glucose deprivation (OGD) and 2 hr reperfusion treated C6 cells; -
FIG. 3A illustrates SIRT1 levels increased in OGD Rat L-6 cells treated with RME, HFE, or both; -
FIG. 3B illustrates quantifiable increases in SIRT1 levels in OGD treated Rat L-6 cells; -
FIG. 4A illustrates CLOCK protein levels increased in OGD Rat L-6 cells treated with RME, HFE, or both; -
FIG. 4B illustrates quantifiable increases in CLOCK levels in OGD treated Rat L-6 cells by RME, HFE, or both; -
FIG. 5A illustrates Bmal1 protein levels increased in OGD Rat L-6 cells treated with RME, HFE, or both; -
FIG. 5B illustrates quantifiable increases in Bmal1 levels in OGD treated Rat L-6 cells by RME, HFE, or both; - The following description of particular aspect(s) is merely exemplary in nature and is in no way intended to limit the scope of the invention, its application, or uses, which may, of course, vary. The invention is described with relation to the non-limiting definitions and terminology included herein. These definitions and terminology are not designed to function as a limitation on the scope or practice of the invention but are presented for illustrative and descriptive purposes only. While the processes or compositions are described as an order of individual steps or using specific materials, it is appreciated that steps or materials may be interchangeable such that the description of the invention may include multiple parts or steps arranged in many ways as is readily appreciated by one of skill in the art.
- Provided are processes for treating, preventing, or modulating a disease or condition related to circadian rhythm machinery component in a subject. Altering a circadian rhythm machinery component is understood as altering, optionally increasing, the expression level, post-translational modification state, nuclear or cytoplasmic location or translocation, or RNA expression rate of a protein normally involved in a 24-hour or other regular cycle in one or more cell types in a subject. A circadian machinery component is optionally RNA or protein, or modifications thereof that are or encode CLOCK, BMAL1, SIRT1, FBXL3, FBXL21, or combinations thereof.
- A disease or condition (e.g. disorder) is one that is due to an irregularity, undesirable expression characteristic, or other element that is caused directly or indirectly by one or more of CLOCK, BMAL1, SIRT1, FBXL3, or FBXL21, or RNA encoding one or more of such proteins. A process includes administering to a subject having a disease or condition associated with an undesirable circadian rhythm function and in need of such treatment an effective amount of an extract of rosemary, an extract of hemerocallis fulva, active portion thereof, or combinations thereof or a dietary supplement containing in whole or in part of an extract of rosemary, an extract of hemerocallis fulva, active portion thereof, or combinations thereof. Such an administration is at an administration time. The administration of the extract of rosemary, an extract of hemerocallis fulva, active portion thereof, or combinations thereof or a dietary supplement containing such will alter an expression characteristic of a protein of CLOCK, BMAL1, FBXL3, FBX121, SIRT1, or combinations thereof in the subject. As such, the invention has utility for treating, preventing, or otherwise modulating a condition caused directly or indirectly by altering or adjusting one or more expression characteristics of a protein involved in a circadian rhythm in a cell.
- It is appreciated herein that the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. The term “including” is used to mean “including but not limited to.”
- An “expression characteristic” is the transcription of a gene encoding a circadian rhythm protein, translation of RNA encoding a circadian rhythm protein, localization of RNA encoding a circadian rhythm protein, protein function, protein localization, protein post-translational modification, or other parameter recognized in the art related to protein expression and function.
- In some aspects, the disease or condition is a sleep disorder, optionally insomnia, jet lag, shift work sleep disorder, delayed sleep phase syndrome (DSPS), advanced sleep phase syndrome (ASPS), a non-24-hour sleep wake disorder or irregular sleep-wake pattern. In some aspects, disease or condition is a psychiatric disorder associated with circadian rhythm, optionally depression. In some aspects, the disease or disorder is a neurological disease with a circadian rhythm component, optionally Alzheimer's disease or anorexia nervosa. In some aspects, the disease or disorder is abnormal blood pressure. In some aspects, the disease or disorder is abnormal heart rate. In some aspects, the disease or disorder is asthma. In some aspects, the disease or disorder the treatment of which benefits from increasing or decreasing metabolite levels, such as levels of NAD, NAM or NMN. In some aspects, a disease or condition is excess fat tissue, elevated body mass index, or other weight disorder. In some aspects, a disease or condition is or is an increased risk of a brain injury such as by ischemic stroke. In some aspects a disease or condition is related to free radical induced degeneration of brain tissue. In some aspect, a disease or condition is less than desirable muscle mass. In some aspects, a disease or condition is the need for muscle recovery following exercise. In some aspects, a disease or condition is cortisol suppression. In some aspects, a disease or condition is undesirable testosterone levels. In some aspects, a disease or condition is a hangover or other condition related to abnormal hydration or salt levels. In some aspects, a disease or condition is excess inflammation at one or more sites or systemic inflammation. In some aspects, a disease or condition is atherosclerosis. In some aspects, a disease or condition is hyperglycemia or hypoglycemia. In some aspects, a disease or condition is the presence of a toxin in a subject or liver disorder resulting or related to the presence of a toxin. In some aspects, the disease or disorder is anorexia nervosa. In some aspects, the disease or condition is abnormal blood pressure. In some aspects, the disease or condition is abnormal heart rate. In some aspects, the disease or condition is asthma. In some aspects, the disease or condition is a metabolic disorder. In some aspects, the metabolic disorder is diabetes, abnormal insulin secretion, abnormal plasma glucose levels, obesity, or metabolic syndrome (or element thereof). In some aspects, the disease or condition is cancer. In some aspects, treating comprises ameliorating symptoms of the disease or condition.
- In some aspects, a disease or condition is a metabolic disorder. Specific metabolic disorders, diseases or conditions optionally include insulin resistance, diabetes, diabetes related conditions or disorders, or metabolic syndrome.
- In some aspects, a disease or condition is a cardiovascular disease. Cardiovascular diseases that can be treated or prevented include cardiomyopathy or myocarditis, illustratively idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy. In some aspects, a cardiovascular disease is atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta or other coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, or the popliteal arteries. Other vascular diseases that can be treated or prevented include those related to the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems.
- In some aspects a disease or condition is a neurological disease. Neurological diseases illustratively include neurodegenerative diseases optionally including stroke, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, Multiple Sclerosis (MS), Friedreich's ataxia, Periventricular leukomalacia (PVL), ALS-Parkinson's-Dementia complex of Guam, Wilson's disease, cerebral palsy, progressive supranuclear palsy (Steel-Richardson syndrome), bulbar and pseudobulbar palsy, diabetic retinopathy, multi-infarct dementia, macular degeneration, Pick's disease, diffuse Lewy body disease, prion diseases such as Creutzfeldt-Jakob, Gerstmann-Straussler-Scheinker disease, Kuru and fatal familial insomnia, primary lateral sclerosis, degenerative ataxias, Machado-Joseph disease/spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, spinal and spinobulbar muscular atrophy (Kennedy's disease), familial spastic paraplegia, Wohlfart-Kugelberg-Welander disease, Tay-Sach's disease, multisystem degeneration (Shy-Drager syndrome), Gilles De La Tourette's disease, familial dysautonomia (Riley-Day syndrome), Kugelberg-Welander disease, subacute sclerosing panencephalitis, Werdnig-Hoffmann disease, synucleinopathies (including multiple system atrophy), Sandhoff disease, cortical basal degeneration, spastic paraparesis, primary progressive aphasia, progressive multifocal leukoencephalopathy, striatonigral degeneration, familial spastic disease, chronic epileptic conditions associated with neurodegeneration, Binswanger's disease, and dementia (including all underlying etiologies of dementia).
- In some aspects, a disease or condition is a muscular disease. Muscular diseases illustratively include neuromuscular diseases such as muscular dystrophy and myopathy.
- In some aspects, a disease or condition is a mitochondrial disease. Mitochondrial diseases optionally include KSS (chronic progressive external ophthalmoplegia), MERRF (myoclonus epilepsy associated with ragged-red fibers; Fukuhara syndrome), MELAS, Leber's disease, Leigh encephalopathia and Pearson's disease.
- In some aspects, a disease or condition is an insulin related condition. Insulin resistance disorders include any disease or condition that is caused by or contributed to by insulin resistance. Illustrative non-limiting examples include diabetes, obesity, metabolic syndrome, insulin-resistance syndromes, syndrome X, insulin resistance, high blood pressure, hypertension, high blood cholesterol, dyslipidemia, hyperlipidemia, dyslipidemia, atherosclerotic disease including stroke, coronary artery disease or myocardial infarction, hyperglycemia, hyperinsulinemia and/or hyperproinsulinemia, impaired glucose tolerance, delayed insulin release, diabetic complications, including coronary heart disease, angina pectoris, congestive heart failure, stroke, cognitive functions in dementia, retinopathy, peripheral neuropathy, nephropathy, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis some types of cancer (such as endometrial, breast, prostate, and colon), complications of pregnancy, poor female reproductive health (such as menstrual irregularities, infertility, irregular ovulation, polycystic ovarian syndrome (PCOS)), lipodystrophy, cholesterol related disorders, such as gallstones, cholescystitis and cholelithiasis, gout, obstructive sleep apnea and respiratory problems, osteoarthritis, and prevention and treatment of bone loss, e.g. osteoporosis.
- Provided are materials in the form of botanical extracts, such as an extract of rosemary, an extract of hemerocallis fulva, active portion thereof, or combinations thereof, alone or as part of a dietary supplement that have utility for altering one or more expression characteristics of a protein involved in a circadian rhythm in a subject. The extract, active portion thereof, or dietary supplement may be in pharmaceutical dietary supplement composition in solid, semi-solid, or liquid dosage forms, such as, for example, tablets, chewables, suppositories, pills, capsules, powders, liquids, or suspensions, and may be provided in unit dosages suitable for a single administration. Time release preparations are also contemplated as effective dosage formulations. The compositions may include an effective amount of a selected extract of rosemary, hemerocallis fulva, active portion thereof, or combinations, optionally in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents.
- The extracts are recognized to include an active ingredient as an active portion of an extract, or the sole portion of an extract. “Active ingredient” refers a component present in the extract that renders, directly or indirectly, the intended effect of the extract. In some aspects, an active ingredient is ursolic acid. Extraction parameters such as water quality, heating temperature, drying temperature, heating time, drying time, and filtering processes all contribute to the quality and efficiency of the process. Water quality directly affects the concentration of active ingredient(s). Poor quality water may cause active ingredient(s) to become decomposed or oxidized during or following the extraction process.
- The rosemary or hemerocallis fulva may be obtained from various resources. Rosemary, or Rosmarinus officinalis, is a woody bush native to the Mediterranean region. Extracts of rosemary may be made from Rosmarinus spp. and preferably from the leaves and young flowering tops of fresh rosemary (Rosmarinus officinalis L. and its cultivars). Rosemary extraction may be performed by harvesting the leaves of a rosemary plant and reducing them in size such as by chopping to improve solvent penetration. A typical particle size is optionally 0.5-5.0 mm, or any value or range therebetween. In some aspects, the leaf is chopped into a powder type substance with a particle size of less than 0.5 mm. The chopped plant material is combined with a suitable extraction solvent such as water and/or a low molecular weight alcohol (e.g. C4-C6 alcohol) such as ethanol. The plant material is combined with the solvent for an extraction time of 18 to 36 hours. The extraction temperature is optionally the range 10° C. to 45° C. The resulting extract liquid is separated from the solid material and filtered, optionally with a sterile filter. Optionally, the resulting extract is poured onto nonstick tray and allowed to dry at 80-90° C. Vacuum-spray dry equipment is optionally used for the drying procedure. The resulting dry extract powder is weighed. An extraction ratio is calculated as w/20×100% with w as the weight (g) of the dry extract powder. The sample and water ratio, heat time, volume of water in the second extraction may vary depending on the amount of the raw material used for extraction.
- Extracts of Hemerocallis fulva are optionally obtained from extraction in an extraction solvent such as water and/or low molecular weight alcohol such as ethanol. Extracts are prepared from plants belonging to the genus Hemerocallis of the family Liliaceae of the order Liliales are used. Examples of such plants include Akinowasuregusa (Hemerocallis fulva L. sempervirens M. Hotta or Hemerocallis sempervirens Araki), Honkanzo (Hemerocallis fulva L. var. fulva), Nokanzo (Hemerocallis fulva L. var. longituba Maxim or Hemerocallis longituba Miq.), and Yabukanzo (Hemerocallis fulva L. var. kwanso Regal), An extract is optionally prepared from whole plants or plant parts, such as leaves, stems, and roots.
- In some aspects, an extract is prepared by drying the plant material and optionally cutting the material into a suitable size for extraction, such as the sizes described for rosemary. The plant material is combined with an extraction solvent (e.g. water, aqueous buffer, low molecular weight alcohol, or combinations thereof) that is preheated to a temperature of 60° C. to 100° C. for an extraction time, typically of 20 to 90 minutes. The particulate material is then removed by gravity separation, centrifugation, or filtering, optionally with a filter size suitable for aseptic filtration. The resulting extract is optionally poured onto nonstick tray and allowed to dry at 80-90° C. Vacuum-spray dry equipment is optionally used for the drying procedure. The resulting dry extract powder is weighed. An extraction ratio is calculated as w/20×100% with w as the weight (g) of the dry extract powder. The sample and water ratio, heat time, volume of water in the extraction may vary depending on the amount of the raw material used for extraction.
- In some aspects, a second extraction of either plant material is performed optionally using the same extraction parameters or differing extraction parameters. Optionally, a second extraction is performed in a low molecular weight alcohol optionally of C2-C4. The first and second extraction solutions are optionally combined together and dried.
- In some aspects, an extract includes or consists of ursolic acid as an active ingredient. Ursolic acid is optionally present in an extract at a concentration of 10 weight percent or greater. In some aspects, ursolic acid is present in an extract at a concentration of 25 weight percent or greater. Optionally, ursolic acid is present at a weight percent at or in excess of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, or 99.9.
- While ursolic acid is descried as a component of or the product representing an extract, it is appreciated that the term “extract” may in some aspects include otherwise isolated, purified, or chemically synthesized ursolic acid. As such, an “extract” is in some aspects ursolic acid obtained either by extraction from a natural or non-natural source, or used as a chemically synthesized ursolic acid.
- Depending on the intended mode of administration, the extract can be in pharmaceutical compositions in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, or suspensions, and may be provided in unit dosages suitable for a single administration. Time release preparations are specifically contemplated as effective dosage formulations. The compositions will include an effective amount of the selected extract in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, or diluents.
- In a solid composition aspect, conventional nontoxic solid carriers may include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talc, cellulose, glucose, sucrose and magnesium carbonate. Liquid pharmaceutically administrable compositions may, for example, be prepared by dissolving or dispersing an active compound with optimal pharmaceutical adjuvants in an excipient, such as water, saline, aqueous dextrose, glycerol, or ethanol, to form a solution or suspension. For example, the pharmaceutical composition may contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, for example, sodium acetate or triethanolamine oleate. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's The Science and Practice of Pharmacy (20th Edition).
- In oral administration aspects, fine powders or granules of extract, or a liquid extract may contain diluting, dispersing, or surface active agents. The extract may be presented in water or in syrup, in capsules or sachets in the dry state, or in a non-aqueous solution or suspension. Suspending agents may also be included in tablets, which may include binders and lubricants in a suspension. Flavoring, preserving, suspending, thickening, or emulsifying agents may be also included to modify the taste and texture of the composition. The tablets and granules provided for oral administration may further be coated for ease of digestion.
- In some aspects, the extract containing dietary supplement composition may be combined with one or more other active agents. An active agent optionally functions synergistically with an extract material. Active agents illustratively include vitamins (such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E or vitamin K), antioxidants (such as acai, wolfberry, alpha lipoic acid, astazanthin, or fucoxanthin), or other regulators of one or more circadian rhythm protein (illustratively resveratrol or polygonum), or any combination of the above. The extract according to the present invention is available as a food additive thereto. Examples include foods in a liquid, semi-liquid, solid, paste, or jelly form.
- Processes are provided for treating, preventing, or modulating a condition directly or indirectly related to an expression characteristic of a circadian rhythm protein in a subject. As used herein, a subject is defined as an organism (such as a human, non-human primate, equine, bovine, murine, or other mammal), or a cell. Illustrative examples of cells include neuronal cells, muscle cells, or any other cell that endogenously or exogenously expresses a circadian machinery component protein.
- The inventors unexpectedly discovered that administration of an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof will alter one or more expression characteristics of a circadian rhythm protein. Circadian rhythm protein expression is altered when a cell, optionally a cell in an organism, is contacted by an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof. Illustrative examples of proteins include the proteins CLOCK, BMAL1, FBXL3, FBX121, SIRT1. In some aspects, a protein is not a sirtuin protein.
- The Circadian Locomotor Output Cycles Kaput (CLOCK) protein is optionally altered in one or more expression characteristics in aspects of the invention. Optionally CLOCK protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes. Optionally, an extract is an extract of rosemary that increases expression of a CLOCK protein. Optionally, an extract is an extract of hemerocallis fulva that increases expression of a CLOCK protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of CLOCK protein within 2 hours of administration. Illustratively, CLOCK protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween. Optionally, CLOCK protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- Brain and muscle Arnt-like protein-1 (BMAL1; also known as MOP3 or Arnt3) is a transcription factor known to regulate circadian rhythm. Optionally BMAL1 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes. Optionally, an extract is an extract of rosemary that increases expression of a BMAL1 protein. Optionally, an extract is an extract of hemerocallis fulva that increases expression of a BMAL1 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of BMAL1 protein within 2 hours of administration. Illustratively, BMAL1 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween. Optionally, BMAL1 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- F-box/LRR-repeat protein 3 (FBXL3) is a member of the F-box protein family that functions in phosphorylation-dependent ubiquitination. Optionally FBXL3 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes. Optionally, an extract is an extract of rosemary that increases expression of a FBXL3 protein. Optionally, an extract is an extract of hemerocallis fulva that increases expression of a FBXL3 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of FBXL3 protein within 2 hours of administration. Illustratively, FBXL3 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween. Optionally, FBXL3 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- F-box/LRR-repeat protein 21 (FBXL21) is a member of the F-box protein family that functions in phosphorylation-dependent ubiquitination. Optionally FBXL21 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes. Optionally, an extract is an extract of rosemary that increases expression of a FBXL21 protein. Optionally, an extract is an extract of hemerocallis fulva that increases expression of a FBXL21 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of FBXL21 protein within 2 hours of administration. Illustratively, FBXL21 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween. Optionally, FBXL21 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- Sirtuin 1 (silent mating type information regulation 2 homolog 1) (SIRT1) is a protein involved in deacetylation of proteins that contribute to cellular regulation. Optionally SIRT1 protein expression in the cytoplasm or levels in the nucleus following translocation are increased in the inventive processes. Optionally, an extract is an extract of rosemary that increases expression of a SIRT1 protein. Optionally, an extract is an extract of hemerocallis fulva that increases expression of a SIRT1 protein. Contacting a cell with an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof is shown to increase the expression of SIRT1 protein within 2 hours of administration. Illustratively, SIRT1 protein expression is enhanced (e.g. increased) by a value of 5% to 300% or more, or any value or range therebetween. Optionally, SIRT1 protein expression is enhanced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 125%, 150%, 200%, 250%, 300%, or more.
- Detecting and optionally quantifying circadian protein expression is achieved by any of many methods known in the art. Illustratively, circadian protein expression is detected and optionally quantified by enzyme linked immunosorbent assay (ELISA), mass spectrometry, western blot, gel electrophoresis optionally coupled with staining such as by Coomassie brilliant blue or silver stain, or by target specific stains, flow cytometry, immunoprecipitation, or by other method known in the art. In some aspects, an ELISA is used to detect and optionally quantify circadian protein expression. For example, ELISA kits for SIRT1 and SIRT2 are available from Enzo Lifesciences, Plymouth Meeting, Pa. Kits for other sirtuins are similarly available from commercial sources. Antibodies directed to CLOCK, BMAL1, and SIRT proteins suitable for use in ELISA, western blot, immunofluorescence or other applications are available from Santa Cruz Biotechnology, Santa Cruz, Calif. Anti-FBXL21 and anti-FBXL3 antibodies are available from abcam, Cambridge, Mass.
- A process optionally includes administration of an extract or dietary supplement containing extract at an administration time in an amount effective to treat the disease or condition or otherwise modulate or ameliorate a symptom of such a disease of condition. Administration is optionally once daily, twice daily or more. Administration optionally is done 1, 2, 3, 4 or more times each day. Optionally, administration is done on an as needed basis. Optionally irregularly, or weekly. Optionally, administration is done once or twice weekly such as when a subject is transitioning from one schedule to another such as due to travel, shift work, weekend to work schedule or work to weekend schedule, or other necessary time. Optionally, an administration time is following exercise. Optionally, an administration time when one or more symptoms of a disease or condition are present, or conditions exist that such a symptom is expected or may occur. Optionally, administration is prior to, following, during, or in lieu of a meal, snack or other consumption of food or nutritious drink. Optionally, administration is prior to, during or following the consumption of alcohol. Optionally, an administration time is at the initiation of a work period.
- Administration time is optionally from −4 hours to 12 hours following light exposure. Optionally, administration is from 0 to 12 hours after light exposure. Optionally, an administration time is upon waking independent of the time of day or the onset of light exposure. Optionally, an administration time is in the evening. The inventors have shown that administration of an effective amount of an extract of rosemary, an extract of hemerocallis fulva, or combinations thereof increases the expression of several proteins involved in several circadian processes. An administration time may be tailored to a desired time to have expression of such a protein or collection of proteins expressed to adjust the sleep-wake cycle of a subject, or to improve wakefulness at a desired time with the improvement in wakefulness optionally, not due to improved rest. In some aspects, the extract is administered in a form that releases at certain times, optionally in an extended release form, in a periodic release form, or using a time control pump.
- In a typical regimen, the extract materials are taken orally between one and three times daily; although, other routes of administration may be utilized. Also, it should be noted that the extracts of the present invention may be utilized in the form of derivatives. For example, the extracts may be bonded, chemically or physically, to other species and moieties such as synthetic polymers, liposomes, small organic molecules, chitin, chitosan, other biopolymers and the like. In view of the teaching presented herein, still further combinations will be readily apparent to those of skill in the art.
- A subject is administered a composition in a dosage so that each dose of the extract supplement selected to deliver an amount of active agent suitable to have an effect on an expression characteristic of a circadian protein. Variable dosing regimens are operative. While in some instances, a single dose treatment may be effective in producing therapeutic effects, in other instances a treatment period in the range of, for example, six weeks to three or six months or more may be utilized. The composition may be administered orally, parentally, or intravenously, intramuscularly, intraperitoneally, by transdermal injection, or by contact with a cell or tissue such as by immersion or other form of contact. Injectables may be prepared in conventional forms, either liquid solutions or suspensions, solid forms suitable for solution or prior to injection, or as suspension in liquid prior to injection or as emulsions.
- The extracts may be provided in sterile form and contain an effective amount of one or more agents for producing the desired response in a unit of weight or volume suitable for administration to a subject. The doses of extracts or dietary supplements containing gone or more of the extracts are administered to a subject can be chosen in accordance with different parameters in accordance with the mode of administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. The dosage of a pharmacological agent may be adjusted by the individual physician or veterinarian, particularly in the event of any complication.
- The dose of the composition may vary depending on the age, weight, general condition of the subject. For example, dosage is in the range of 1-1,000 mg of equivalent of dry extract powder extract per day may be an effective range. In some aspects, a dosage is between 10 and 800 mg per day, optionally from 100 to 600 mg per day, optionally 200-400 mg per day, optionally 400 mg per day. Dosage is optionally 1, 2, 3, 4, or more times daily. Optionally, dosage is twice daily. Optionally, dosage is 200 mg twice daily. The extract may also comprise 0.01%-100% of the dry weight of the composition. For example, a dietary supplement composition may comprise 20%-50% of the dry weight of the extract composition. An “effective amount” is defined as that capable of altering one or more expression characteristics of a circadian protein or a gene encoding a circadian protein relative to a control.
- An extract optionally is or is a part of a dietary supplement composition. An extract is optionally present in a dietary supplement composition at 10%-100% by weight, optionally 20%-50% by weight, optionally 30%-40% by weight, or any value or range between 10% and 100% of the dry weight of the dietary supplement composition.
- Various aspects of the present invention are illustrated by the following non-limiting examples. The examples are for illustrative purposes and are not a limitation on any practice of the present invention. It will be understood that variations and modifications can be made without departing from the spirit and scope of the invention.
- It was investigated whether an extract of rosemary (RME) and an extract of hemerocallis fulva (HFE) regulate key circadian protein expression in normal rat C6 glioma cells and IPEC-1 (Porcine intestinal epithelial cell lines), using immunofluorescence and western blotting analyses. Oxygen and circadian rhythmicity are essential in a myriad of physiological processes to maintain homeostasis, from blood pressure and sleep/wake cycles, down to cellular signaling pathways that play critical roles in health and disease. Oxidative stress can induce the dysregulated circadian rhythms. We also test if RME and HFE attenuate the damages of these proteins expression from oxygen-glucose deprivation (OGD).
- The dried rosemary extract and hemerocallis fulva extract were provided by Integrity Nutraceuticals International (Spring Hill, Tenn., USA). The dried powder of each extract contains 25% ursolic acid. To obtain a more pure extract fraction, the dried rosemary or Hemerocallis fulva powder (1 g) was incubated with an aqueous phosphate buffer solution 0.01 M, pH 7.4 (5 mL), at 60° C. for 4 hours, then centrifuged at 6000 rpm for 15 minutes. The supernatant was filtrated by 40 μm filter mesh and saved for the concentration evaluation. Aliquots of RME and HFE were prepared at 10 mg/mL and stored at −20° C. for use in subsequent studies.
- C6 glioma cells (CCL-107) were purchased from American Type Culture Collection (ATCC; Manassas, Va.). Cell cultures were grown in F-12 K medium (Gibco/Invitrogen) supplemented with 10% horse serum and 2% fetal bovine serum and maintained at 37° C. with 5% CO2/95% air. Cultures were grown to 85% confluency in 75 mm flasks and, after trypsinization, were seeded in 35 mm culture dishes or 6 well plates; and grown to confluence during the experimental period. All cultures were used in the experiments between passages 22 and 32. Plated cells were grown for 2 days before treatment with an extract or control.
- Culture of IPEC-1 cells was carried out at 37° C. in an atmosphere containing 5% CO2. Undifferentiated IPEC-1 cells were maintained in serial passage in growth medium (GM): DMEM/F12 medium supplemented with 5% FBS, insulin, transferrin (ITS Premix), epidermal growth factor, penicillin and streptomycin. Cells were maintained in serum-containing GM for 48 h for the experiments.
- The effects of the RME or HFE were studied in cells by staining for target proteins using the following primary antibodies all provided by Abcam Inc, Cambridge, Mass. SIRT1 was detected by ab110304 Mouse monoclonal [19A7AB4]. KAT13D/CLOCK was detected using ab134165 Rabbit monoclonal [EPR6227]. BMAL1 was detected using the C-terminal recognizing antibody ab140646 Rabbit monoclonal [EPR8355(2)]. FBXL3 was detected using ab96645 Rabbit polyclonal. FBXL21 was detected using ab57302 Mouse monoclonal. For each immunofluorescence study the cells were stained with the primary antibody for the target of interest followed by incubation with AlexaFluor® 594-conjugated normal rabbit IgG (green) or AlexaFluor® 488-conjugated normal mouse IgG (red).
- C6 cells were treated with saline with or without RME (20, 50 and 100 μg/mL) or without HFE (50, 100 and 200 μg/mL) in the medium for 2 h at 37° C. The effects of rosemary extract (RME) and hemerocallis fulva extract (HFE) on circadian locomoter output cycles protein kaput (CLOCK) protein expression in C6 glioma cells are determined by immunofluorescence. A2 h treatment with RME or HFE significantly induced increased the intensity of immunofluorescence of CLOCK compared with the controls indicating enhanced CLOCK protein expression.
- Similar results of RME and HFE on CLOCK protein expression were observed in IPEC-1 cells. IPEC-1 cells were treated with saline with or without RME (20, 50 and 100 μg/mL) or with or without HFE (50, 100 and 200 μg/mL) in the medium for 6 h at 37° C. 6 h RME and HFE treatment significantly induced the intensity of immunofluorescence of CLOCK compared with the controls.
-
FIG. 1 illustrates the effects of RME and HFE on CLOCK (FIG. 1A ) and BMAL1 (FIG. 1B ) protein expression in C6 cells. C6 cells were treated with saline with or without RME (20 and 50 μg/mL) or with or without HFE (50 and 100 μg/mL) in the medium for 7 h at 37° C. Representative immunoblots show increased expression in RME and HFE treated C6 cells. - Oxygen glucose deprivation (OGD) was induced in cultures as described by Panickar et al. (Panickar et al., 2009a). Briefly, cultures were washed twice with a balanced salt solution (BSS) with the following composition (in mM): NaCl 116, KCl 5.4, CaCl2 1.8, MgSO4 0.8, NaH2PO4 0.83, NaHCO3 24 and phenol red 0.001 w/v; pH 7.4. Following washes, BSS was added to the cultures and placed in an airtight container (Billups chamber; Billups-Rothenberg Inc., Del Mar, Calif.) and continuously flushed with 95% N2/5% CO2 for 5 hr. Following the OGD, BSS was removed and normal media was added immediately afterwards.
- Oxygen-glucose deprivation (OGD)-induced decreased CLOCK expression is reversed and further enhanced by RME and HFE in IPEC-1 cells. The RME and HFE were added to the media during 4 hr OGD and added to normal media for other 3 hr, immediately after the end of 4 hr OGD at 37° C. Sample photomicrographs of CLOCK fluorescence after 4 hr OGD and 3 h reperfusion in normal control (CON), OGD, and OGD+two dosages RME or
HFE 100 μg/ml or 200 μg/ml illustrate increases in CLOCK expression relative to control and OGD treated cells. - Immunofluorescence measurements demonstrated that RME and HFE each increased FBXL3 protein levels in 4 hr oxygen-glucose deprivation (OGD) and 2 hr reperfusion treated C6 glioma cells. The RME or HFE were added to the media during 4 hr OGD and added to normal media for other 2 hr, immediately after the end of 4 hr OGD at 37° C. Sample photomicrographs of FBXL3 fluorescence after 4 hr OGD and 2 h reperfusion in OGD, and OGD+two dosages RME and
HFE 50 μg/ml or 100 μg/ml illustrate enhanced expression of FBXL3 due to the presence of the extract. - RME (A) and HFE (B) both increased FBXL3 protein levels in 4 hr oxygen-glucose deprivation (OGD) and 2 hr reperfusion treated IPEC-1 cells as illustrated by immunofluorescence. The RME and HFE were added to the media during 4 hr OGD and added to normal media for other 3 hr, immediately after the end of 4 hr OGD at 37° C. Sample photomicrographs of FBXL3 fluorescence after 4 hr OGD and 3 h reperfusion in OGD, and OGD+RME or HFE at either 50 μg/ml or 100 μg/ml demonstrate enhanced expression of FBXL3 protein due to extract exposure.
-
FIG. 2 illustrates RME increased BMAL1 (A) and FBXL21 (B) protein levels in 4 hr oxygen-glucose deprivation (OGD) and 2 hr reperfusion treated C6 cells. The RME was added to the media during 4 hr OGD and added to normal media for other 2 hr, immediately after the end of 4 hr OGD at 37° C. The blot bands are detected by Odyssey® Western Blotting. Briefly, the blot was probed with rabbit anti-BMAL1 or mouse anti-FBX121 followed by detection with IRDye® 800CW Goat anti-Rabbit IgG (LI-COR P/N 926-32231) or IRDye 680RD Goat anti-Mouse IgG (LI-COR P/N 926-68070). Sample photomicrographs of FBXL21 fluorescence after 4 hr OGD and 2 h reperfusion in OGD, and OGD+two dosages RME are illustrated. - The effects of RME or HFE on SIRT1 protein expression in 4 hr oxygen-glucose deprivation (OGD) and 2 hr reperfusion treated C6 cells were examined by immunofluorescence. The RME or HFE were added to the media during 4 hr OGD and added to normal media for other 2 hr, immediately after the end of OGD at 37° C. SIRT1 fluorescence was increased in RME and HFE at either 50 μg/ml or 100 μg/ml in 4 hr OGD and 2 hr reperfusion treated C6 cells.
- Rat L-6 myogenic cell line (ATCC) were grown as a monolayer in DMEM with 10% fetal bovine serum (FBS) at 37° C. in a humidified incubator with 5% CO2. L-6 cells (0.5×106) were seeded on 6-well plates. Experiments were initiated 48 hr after plating. For oxygen-glucose deprivation (OGD) of the L-6 cells, the culture media was replaced with hypoglycemic media and placed in an airtight Billups chamber and flushed with 95% N2/5% CO2 for 4 hr. Following OGD treatment, hypoglycemic media was replaced with regular media and returned to the incubator, with or without RME, HFE or the mixture of RME/HFE for 20 hr. After treatment, the cells were washed twice with cold PBS, and harvested by scraping in 200 μl of lysis buffer. Eighty micrograms of protein, which was determined by Bradford assay (Bio-Rad protein assay kit) was separated electrophoretically using a 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel and transferred to a nitrocellulose membrane. The membrane was incubated at room temperature in Odyssey blocking buffer including 0.05% Tween-20 containing primary antibodies as above directed to one of the following: SIRT1 (1:500), CLOCK (1:2000), Bmal1 (1:1000), or β-actin (1:1000). After washing with TBS-T three times, the membrane was incubated with anti-mouse or rabbit IRDye secondary antibodies (1:10,000) for 1 h at room temperature. Quantitative IR western blot detection was performed with Odyssey CLx Imager. Data were analyzed by one-way analysis of variance followed by post-hoc analysis of between group mean differences by Fisher's Least Significant Difference (LSD) test. Different superscripts indicate significant differences among groups (p<0.05).
- As illustrated in
FIG. 3A , SIRT1 levels are increased in OGD treated L-6 cells by RME and/or HFE. The quantified amounts of protein are illustrated inFIG. 3B demonstrating significantly increased amounts of SIRT1 levels relative to control. An additional effect is observed in RME+HFE mixture treated cells on SIRT1 expression, compared with individual RME or HFE only treated cells. -
FIG. 4 illustrates CLOCK protein levels increased in OGD treated L-6 cells by RME and/or HFE. RME, HFE, or both significantly enhance CLOCK protein expression in OGD treated L6 skeletal muscle cells. An additional effect in RME+HFE mixture treated cells on CLOCK expression is also observed compared to individual RME or HFE only treated cells. -
FIG. 5 illustrates Bmal1 protein levels increased in OGD treated L-6 cells by RME and/or HFE. RME, HFE, or both significantly enhance Bmal1 protein expression in OGD treated L-6 skeletal muscle cells. An additional effect is observed in cells treated with the RME+HFE compared with individual RME or HFE only treated cells. - Overall, a method for regulating expression of five key proteins linked to circadian rhythm disorders (CLOCK, BMAL1, FBXL3, FBXL21 and SIRT1) is described characterized by modulating expression in normal conditions and oxidative stress conditions in Rat Cr brain glioma cells, Rat L-6 myogenic cells, and IPEC-2 cells. Both extracts, RME and HFE, each significantly modulate the expression of circadian clock proteins in all cell types, and reverse cell damages identified by reductions of the key proteins related to circadian rhythms induced by oxidative stress. These results indicate that RME and HFE extracts are useful as a new approach to attenuate the disruption of circadian rhythms, or to modulate circadian rhythm in a subject.
- iPEC-1 cells were grown as a monolayer in DMEM with 10% fetal bovine serum (FBS) and the necessary supplements at 37° C. in a humidified incubator with 5% CO2. iPEC1 cells were seeded on 35 mm dishes. Experiments were initiated 48 hr after plating. Cells were treated with saline or with ursolic acid at three separate dosages (1 μM; 5 μM; or 20 μM) in the medium for 24 hr at 37° C. The cells were then washed with ice-cold PBS and fixed with 4% paraformaldehyde for 10 min at room temperature followed by permeabilization with 0.3% Triton X-100 for 10 min. After being washed with PBS three times, cells were incubated for 1 hr in PBS containing 10% normal goat serum blocking solution. The cells were subjected to immunofluorescence staining with the target specific antibodies (SIRT1, CLOCK and Bmal1) overnight at 4° C. The cells were then washed with cold PBS three times for 3 min each, and incubated with Alexa-labeled secondary antibodies (Invitrogen) at room temperature for 1 h. The cells were examined by fluorescence microscopy (a Nikon TE2000-S microscope, Nikon, Tokyo, Japan).
- 24 hour incubation with ursolic acid significantly induced the intensity of immunofluorescence of SIRT1, CLOCK and Bmal1 compared with controls at all three concentrations of ursolic acid tested as evidenced by immunofluorescence staining. Scientific and technical terms used herein are intended to have the meanings commonly understood by those of ordinary skill in the art. Such terms are found defined and used in context in various standard references illustratively including J. Sambrook and D. W. Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 3rd Ed., 2001; F. M. Ausubel, Ed., Short Protocols in Molecular Biology, Current Protocols; 5th Ed., 2002; B. Alberts et al., Molecular Biology of the Cell, 4th Ed., Garland, 2002; D. L. Nelson and M. M. Cox, Lehninger Principles of Biochemistry, 4th Ed., W.H. Freeman & Company, 2004; Wild, D., The Immunoassay Handbook, 3rd Ed., Elsevier Science, 2005; Gosling, J. P., Immunoassays: A Practical Approach, Practical Approach Series, Oxford University Press, 2005; Antibody Engineering, Kontermann, R. and Diibel, S. (Eds.), Springer, 2001; Harlow, E. and Lane, D., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988; Ausubel, F. et al., (Eds.), Short Protocols in Molecular Biology, Wiley, 2002; J. D. Pound (Ed.) Immunochemical Protocols, Methods in Molecular Biology, Humana Press; 2nd ed., 1998; B. K. C. Lo (Ed.), Antibody Engineering: Methods and Protocols, Methods in Molecular Biology, Humana Press, 2003; and Kohler, G. and Milstein, C., Nature, 256:495-497 (1975); the contents of each of which are incorporated herein by reference.
- Methods involving conventional biological techniques are described herein. Such techniques are generally known in the art and are described in detail in methodology treatises such as Molecular Cloning: A Laboratory Manual, 3rd ed., vol. 1-3, ed. Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001; Current Protocols in Molecular Biology, ed. Ausubel et al., Greene Publishing and Wiley-Interscience, New York, 1992 (with periodic updates); and Short Protocols in Molecular Biology, ed. Ausubel et al., 52 ed., Wiley-Interscience, New York, 2002. Immunological methods (e.g., preparation of antigen-specific antibodies, immunoprecipitation, and immunoblotting) are described, e.g., in Current Protocols in Immunology, ed. Coligan et al., John Wiley & Sons, New York, 1991; and Methods of Immunological Analysis, ed. Masseyeff et al., John Wiley & Sons, New York, 1992.
-
- 1. Schulz P, Steimer T: Neurobiology of circadian systems. CNS. Drugs 23 Suppl 2:3-13, 2009
- 2. Buijs R M, Kalsbeek A: Hypothalamic integration of central and peripheral clocks. Nat. Rev. Neurosci. 2:521-526, 2001
- 3. Bray M S, Young M E: Circadian rhythms in the development of obesity: potential role for the circadian clock within the adipocyte. Obes. Rev. 8:169-181, 2007
- 4. Gale J E, Cox H I, Qian J, et al: Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction. J. Biol. Rhythms 26:423-433, 2011
- 5. Shaw E, Tofler G H: Circadian rhythm and cardiovascular disease. Curr. Atheroscler. Rep. 11:289-295, 2009
- 6. Wyatt J K: Circadian rhythm sleep disorders. Pediatr. Clin. North Am. 58:621-635, 2011
- 7. Quera Salva M A, Hartley S, Barbot F, et al: Circadian rhythms, melatonin and depression. Curr. Pharm. Des 17:1459-1470, 2011
- 8. Schibler U, Ripperger J, Brown S A: Peripheral circadian oscillators in mammals: time and food. J. Biol. Rhythms 18:250-260, 2003
- 9. Jung-Hynes B, Ahmad N: SIRT1 controls circadian clock circuitry and promotes cell survival: a connection with age-related neoplasms. FASEB J. 23:2803-2809, 2009
- 10. Chang H C, Guarente L: SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 153:1448-1460, 2013
- 11. Chang H C, Guarente L: SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 153:1448-1460, 2013
- 12. Hirano A, Yumimoto K, Tsunematsu R, et al: FBXL21 regulates oscillation of the circadian clock through ubiquitination and stabilization of cryptochromes. Cell 152:1106-1118, 2013
- 13. Sanjust E, Mocci G, Zucca P, et al: Mediterranean shrubs as potential antioxidant sources. Nat. Prod. Res. 22:689-708, 2008
- 14. Harach T, Aprikian O, Monnard I, et al: Rosemary (Rosmarinus officinalis L.) leaf extract limits weight gain and liver steatosis in mice fed a high-fat diet. Planta Med. 76:566-571, 2010
- 15. Tu Z, Moss-Pierce T, Ford P, et al: Rosemary (Rosmarinus officinalis L.) Extract Regulates Glucose and Lipid Metabolism by Activating AMPK and PPAR Pathways in HepG2 Cells. J. Agric. Food Chem. 2013
- 16. Bakirel T, Bakirel U, Keles O U, et al: In vivo assessment of antidiabetic and antioxidant activities of rosemary (Rosmarinus officinalis) in alloxan-diabetic rabbits. J. Ethnopharmacol. 116:64-73, 2008
- 17. Uezu E: Effects of Hemerocallis on sleep in mice. Psychiatry Clin. Neurosci. 52:136-137, 1998
- 18. Que F, Mao L, Zheng X: In vitro and vivo antioxidant activities of daylily flowers and the involvement of phenolic compounds. Asia Pac. J. Clin. Nutr. 16 Suppl 1:196-203, 2007
- 19. Wilking M, Ndiaye M, Mukhtar H, et al: Circadian rhythm connections to oxidative stress: implications for human health. Antioxid. Redox. Signal. 19:192-208, 2013
- 20. Hardeland R, Coto-Montes A, Poeggeler B: Circadian rhythms, oxidative stress, and antioxidative defense mechanisms. Chronobiol. Int. 20:921-962, 2003.
- 21. U.S. Application Publication No: 2011/0076349
- 22. WO 2001/080818 A1
- Various modifications of the present invention, in addition to those shown and described herein, will be apparent to those skilled in the art of the above description. Such modifications are also intended to fall within the scope of the appended claims.
- It is appreciated that all reagents are obtainable by sources known in the art unless otherwise specified.
- Patents, publications, and applications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents, publications, and applications are incorporated herein by reference to the same extent as if each individual patent, publication, or application was specifically and individually incorporated herein by reference.
- The foregoing description is illustrative of particular aspects of the invention, but is not meant to be a limitation upon the practice thereof. The following claims, including all equivalents thereof, are intended to define the scope of the invention.
Claims (49)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/431,097 US20160256511A1 (en) | 2013-11-13 | 2014-11-13 | Compositions and methods for the treatment or prophylaxis of circadian protein related conditions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361903434P | 2013-11-13 | 2013-11-13 | |
US201361903440P | 2013-11-13 | 2013-11-13 | |
PCT/US2014/065374 WO2015073628A1 (en) | 2013-11-13 | 2014-11-13 | Treatment or prophylaxis of circadian protein related conditions |
US14/431,097 US20160256511A1 (en) | 2013-11-13 | 2014-11-13 | Compositions and methods for the treatment or prophylaxis of circadian protein related conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160256511A1 true US20160256511A1 (en) | 2016-09-08 |
Family
ID=53057980
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/036,479 Active 2035-09-03 US10039798B2 (en) | 2013-11-13 | 2014-11-13 | Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm |
US14/431,097 Abandoned US20160256511A1 (en) | 2013-11-13 | 2014-11-13 | Compositions and methods for the treatment or prophylaxis of circadian protein related conditions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/036,479 Active 2035-09-03 US10039798B2 (en) | 2013-11-13 | 2014-11-13 | Extracts of rosemary or hemerocallis fulva and methods of using same to promote circadian rhythm |
Country Status (5)
Country | Link |
---|---|
US (2) | US10039798B2 (en) |
EP (1) | EP3068415A4 (en) |
JP (1) | JP6473759B2 (en) |
CN (1) | CN105979954A (en) |
WO (2) | WO2015073598A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6993819B2 (en) * | 2017-09-05 | 2022-01-14 | 株式会社ニップン | Circadian rhythm regulator |
WO2020000457A1 (en) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | Grna targeting sequence that specifically targets human kat13d gene and use thereof |
EP3590359A1 (en) * | 2018-07-03 | 2020-01-08 | Centre National De La Recherche Scientifique | Taxodione for its use for protecting muscle and meat from oxidation |
TWI789553B (en) * | 2019-10-18 | 2023-01-11 | 大江生醫股份有限公司 | Use of hemerocallis fulva linn. extract for manufacturing of a composition for promoting skeletal muscle basal metaboilc rate |
CN111920735B (en) * | 2020-08-21 | 2022-02-08 | 广东盛普生命科技有限公司 | Plant-derived anti-aging composition and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004075638A (en) * | 2002-08-21 | 2004-03-11 | Okinawa Pref Gov | Functional material having action to suppress increase of blood sugar level and suppress increase of blood pressure |
US20090011041A1 (en) * | 2004-04-26 | 2009-01-08 | Musaeva Adilya Rafik Kyzy | Compositions for Correcting Age Related Changes of a Human Endocrine System and Methods for Producing a Pharmaceutical Form Bases on Said Compositions |
CN101422465A (en) * | 2007-10-30 | 2009-05-06 | 上海市新文达生物科技有限公司 | Use of ursolic acid and plant extract containing the same |
US20110076349A1 (en) * | 2008-05-30 | 2011-03-31 | Koichi Yoshihara | Composition containing hot-water extract of plant of the genus hemerocallis and having antidepressant-like effects or fatigue-relieving effects based on sleep improvement |
CN102416082A (en) * | 2011-11-10 | 2012-04-18 | 孙毅坤 | Traditional Chinese medicine extract used for treating insomnia |
US20120183635A1 (en) * | 2006-11-24 | 2012-07-19 | Dsm Ip Assets B.V. | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094906A (en) * | 1993-05-12 | 1994-11-16 | 郑增问 | Fetus and infant's nutritious food capable of improving growth and development of brain structure |
JP2007508320A (en) | 2003-10-10 | 2007-04-05 | アクセス ビジネス グループ インターナショナル エルエルシー | A composition comprising rosmarinusofficinalis plant extract, Centella, Echinacea or Alpinia plant extract, and DNA repair enzyme |
EP2008662B1 (en) * | 2006-04-07 | 2012-08-22 | Kao Corporation | Lipolysis stimulator |
EP1925214A1 (en) * | 2006-11-24 | 2008-05-28 | DSMIP Assets B.V. | Dietary and pharmaceutical compositions containing carnosol and/or rosmanol and their uses |
EP1925313A1 (en) * | 2006-11-24 | 2008-05-28 | Nestec S.A. | Prevention and treatment of disorders connected to impaired neurotransmission |
JP5414192B2 (en) * | 2007-03-29 | 2014-02-12 | 江崎グリコ株式会社 | Circadian rhythm adjustment composition |
CN101040901A (en) * | 2007-04-12 | 2007-09-26 | 云南龙润药业有限公司 | Rosmarinus officinalis extract and its preparing process and application |
US8703161B2 (en) * | 2007-08-13 | 2014-04-22 | Elc Management, Llc | Skin repair compositions comprising circadian gene activators and a synergistic combination of Sirt1 gene activators |
JP5868312B2 (en) * | 2010-03-31 | 2016-02-24 | 株式会社 資生堂 | Expression regulator of clock gene Bmal |
JP5808797B2 (en) * | 2010-05-20 | 2015-11-10 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Methods for inhibiting muscle atrophy |
JP5923238B2 (en) * | 2010-07-07 | 2016-05-24 | アサヒグループホールディングス株式会社 | Vagus nerve activator |
CA2823397C (en) * | 2011-01-07 | 2020-03-10 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
WO2012142511A2 (en) * | 2011-04-15 | 2012-10-18 | Md Matrix Health Llc Dba Md Matrix Health Inc | Orthomolecular compositions and their use in stabilizing the extracellular matrix |
CN102228250B (en) * | 2011-07-08 | 2012-12-19 | 北京工商大学 | Functional food for sleep improvement and preparation method thereof |
JP2013184921A (en) | 2012-03-07 | 2013-09-19 | Shiseido Co Ltd | Expression modulator for clock gene |
-
2014
- 2014-11-13 WO PCT/US2014/065336 patent/WO2015073598A1/en active Application Filing
- 2014-11-13 US US15/036,479 patent/US10039798B2/en active Active
- 2014-11-13 EP EP14862727.6A patent/EP3068415A4/en not_active Withdrawn
- 2014-11-13 CN CN201480073023.3A patent/CN105979954A/en active Pending
- 2014-11-13 US US14/431,097 patent/US20160256511A1/en not_active Abandoned
- 2014-11-13 WO PCT/US2014/065374 patent/WO2015073628A1/en active Application Filing
- 2014-11-13 JP JP2016554316A patent/JP6473759B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004075638A (en) * | 2002-08-21 | 2004-03-11 | Okinawa Pref Gov | Functional material having action to suppress increase of blood sugar level and suppress increase of blood pressure |
US20090011041A1 (en) * | 2004-04-26 | 2009-01-08 | Musaeva Adilya Rafik Kyzy | Compositions for Correcting Age Related Changes of a Human Endocrine System and Methods for Producing a Pharmaceutical Form Bases on Said Compositions |
US20120183635A1 (en) * | 2006-11-24 | 2012-07-19 | Dsm Ip Assets B.V. | Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses |
CN101422465A (en) * | 2007-10-30 | 2009-05-06 | 上海市新文达生物科技有限公司 | Use of ursolic acid and plant extract containing the same |
US20110076349A1 (en) * | 2008-05-30 | 2011-03-31 | Koichi Yoshihara | Composition containing hot-water extract of plant of the genus hemerocallis and having antidepressant-like effects or fatigue-relieving effects based on sleep improvement |
CN102416082A (en) * | 2011-11-10 | 2012-04-18 | 孙毅坤 | Traditional Chinese medicine extract used for treating insomnia |
Also Published As
Publication number | Publication date |
---|---|
CN105979954A (en) | 2016-09-28 |
US20160296581A1 (en) | 2016-10-13 |
JP2016537426A (en) | 2016-12-01 |
JP6473759B2 (en) | 2019-02-20 |
EP3068415A4 (en) | 2017-09-13 |
WO2015073628A1 (en) | 2015-05-21 |
WO2015073598A1 (en) | 2015-05-21 |
US10039798B2 (en) | 2018-08-07 |
EP3068415A1 (en) | 2016-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160256511A1 (en) | Compositions and methods for the treatment or prophylaxis of circadian protein related conditions | |
Ma et al. | Huperzine A promotes hippocampal neurogenesis in vitro and in vivo | |
Min et al. | The alterations of Ca2+/calmodulin/CaMKII/CaV1. 2 signaling in experimental models of Alzheimer's disease and vascular dementia | |
KR102114017B1 (en) | Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same | |
Abuznait et al. | Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products | |
Nepal et al. | Kaempferol induces chondrogenesis in ATDC5 cells through activation of ERK/BMP-2 signaling pathway | |
Li-Hua et al. | Esculentoside A inhibits LPS-induced BV2 microglia activation through activating PPAR-γ | |
An et al. | Crocin regulates the proliferation and migration of neural stem cells after cerebral ischemia by activating the Notch1 pathway | |
Kumkarnjana et al. | Flavonoids kaempferide and 4, 2′-dihydroxy-4′, 5′, 6′-trimethoxychalcone inhibit mitotic clonal expansion and induce apoptosis during the early phase of adipogenesis in 3T3-L1 cells | |
Aleshin et al. | Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) protects against ceramide-induced cellular toxicity in rat brain astrocytes and neurons by activation of ceramide kinase | |
Ren et al. | Thioredoxin is implicated in the anti‑apoptotic effects of grape seed proanthocyanidin extract during hyperglycemia | |
Stafeev et al. | Chemical inducers of obesity-associated metabolic stress activate inflammation and reduce insulin sensitivity in 3T3-L1 adipocytes | |
US9238015B2 (en) | 4-oxo-2-pentenoic acid and cardiovascular health | |
Singh et al. | Characterizing ischaemic tolerance in rat pheochromocytoma (PC12) cells and primary rat neurons | |
JP6557893B1 (en) | Composition for prevention, reduction and / or treatment of heat stroke | |
KR20120115963A (en) | Composition for prevention or treatment of cardiovascular disease containing extracts of dioscorea batatas decne | |
Lee et al. | Anti-diabetic activities of ethanol extracts from persimmon leaves | |
KR101187715B1 (en) | Novel TRPV3 inhibitor and use thereof | |
Ghorbani et al. | Physiological effects of proinsulin-connecting peptide in human subcutaneous adipose tissue | |
Senthilkumar et al. | Cannabidiol and Indole-3-carbinol Reduce Intracellular Lipid Droplet Accumulation in HepaRG, A Human Liver Cell Line, as well as in Human Adipocytes | |
KR20160023965A (en) | Pharmaceutical composition for muscle regeneration comprising ursolic acid and leucine | |
JP6570052B2 (en) | Circadian rhythm improving agent | |
KR101118901B1 (en) | PHARMACEUTICAL OR FUNCTIONAL FOODS COMPOSITION FOR PREVENTING OR TREATING DEMENTIA AND IMPROVING COGNITIVE ABILITY COMPRISING AN EXTRACT OF Suaeda asparagoides | |
JP2018154589A (en) | Astrocyte differentiation promoting composition | |
Koga et al. | Peucedanum japonicum Thunb (PJT) Extracts Enhance Adiponectin Secretion in Human Metabolic Stem Cells Screening System and in Healthy Individuals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IN INGREDIENTS, INC., TENNESSEE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:QIN, BOLIN;ROMERO, AUGUSTIN;ROMERO, TIM;REEL/FRAME:036224/0235 Effective date: 20150331 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |